This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Reference
Main reference
Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:1522, caffeine.
Main references
Bordier PJ, Marie PJ, Arnaud CD: Evolution of renal osteodystrophy: Correlation of bone histomorphometry and serum mineral and immunoreactive parathyroid hormone values before and after treatment with calcium carbonate or 25-hydroxycholecalciferol. Kidney Int 7 (Suppl 2):102, 1975
Boris A: Structure-activity relationships of vitamin D analogues. Am J Med 62:543, 1977
Brancaccio D, Graziani G, Galmozzi C, Ponticelli C: 25-Hydroxy-vitamin-D deficiency and osteomalacia of chronic renal failure. Lancet I:199, 1977
Goodman and Gilman’s The pharmacological basis of therapeutics. 7th ed. New York: Macmillan, 1985: 1517, chapter 65, Agents affecting calcification: calcium, parathyroid hormone, calcitonin, vitamin D, and other compounds by RC Haynes and F Murad.
Hahn TJ, Biage SJ, Scharp CR, Avioli LV: Phenobarbital-induced alterations in vitamin D metabolism, J Clin Invest 51:741, 1972
Hahn TJ, Hendin BA, Scharp CR, Haddad JG jr: Effects of chronic anticonvulsant therapy on serum 25-hydroxycalciferol levels in adults. N Engl J Med 287:900, 1972
Henning HV, Fuchs C: Renale Osteopathie. Nieren- und Hoch-druckkrankh 13:235, 1984
Kawashima H, Kurokawa K: Metabolism and sites of action of vitamin D in the kidney. Kidney Int 29:98, 1986
Rutherford WE, Blondin J, Hruska K, Kopelman R, Klahr S, Slatopolsky E: Effect of 25-hydroxycholecalciferol on calcium absorption in chronic renal disease. Kidney Int 8:320, 1975
Silver J, Shvil Y, Fainaru M: Vitamin D transport in an infant with vitamin D toxicity. Br Med J 2:93, 1978
Teitelbaum SL, Bone JM, Stein PM, Gilden JJ, Bates M, Boisseau VC, Avioli LV: Calcifediol in chronic renal insufficiency. Skeletal response. JAMA 235:164, 1976
Main references
Baker RLI, Muir JW, Sharman VL, et al.: Controlled trial of calcitriol in hemodialysis patients. Clin Nephrol 26:185, 1986
Boris A: Structure-activity relationships of vitamin D analogues. Am J Med 62:543, 1977
Dusso A, Lopez-Hilker S, Rapp N, Slatopolsky E: Extra-renal production of calcitriol in chronic renal failure. Kidney Int 34:368, 1988
Feinfeld DA, Sherwood LM: Parathyroid hormone and 1,25(OH)2D3 in chronic renal failure. Kidney Int 33:1049, 1988
Goodman and Gilman’s The pharmacological basis of therapeutics. 7th ed. New York: Macmillan, 1985: 1517, chapter 65, Agents affecting calcification: calcium, parathyroid hormone, calcitonin, vitamin D, and other compounds by RC Haynes and F Murad
Habener JF, Mahaffey JE: Osteomalacia and disorders of vitamin D metabolism. Annu Rev Med 29:327, 1978
Henning HV, Fuchs C: Renale Osteopathie. Nieren-und Hoch-druckkrankh 13:235, 1984
Jubiz W, Haussler MR, McCain TA, Tolman KG: Plasma 1,25-dihydroxyvitamin D levels in patients receiving anticonvulsant drugs. J Clin Endocrinol Metab 44:617, 1977
Kawashima H, Kurokawa K: Metabolism and sites of action of vitamin D in the kidney. Kidney Int 29:98, 1986
Levine BS, Singer FR, Bryce GF, Mallon JP, Miller ON, Coburn JW: Pharmacokinetics and biologic effects of calcitriol in normal humans. J Lab Clin Med 105:239, 1985
Mawer EB, Backhouse J, Davies M, Hill LF, Taylor CM: Metabolic fate of administered 1,25-dihydroxycholecalciferol in controls and in patients with hypoparathyroidism. Lancet I:1203, 1976
Slatopolsky E, Weerts C, Thielan J, Horst R, Harter H, Martin KJ: Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxycholecalciferol in uremic patients. J Clin Invest 74:2134, 1984
Main references
Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:1079, calcium carbonate
Slatopolsky E, Weerts C, Lopez-Hilker S, Norwood K, Zink M, Windus D, Delmez J: Calcium carbonate as a phosphate binder in patients with chronic renal failure undergoing dialysis. N Engl J Med 315:157, 1986
Main reference
Benakis A, Glasson B, Bouvier CA, Ritschard J, Krahenbuhl B, Jung A, Hachen HJ: Metabolisme et pharmacocinetique du dobesilate de calcium chez l’homme. Thérapie (Paris) 29:211, 1974
Main reference
Nixon PF, Bertino JR: Effective absorption and utilization of oral formyltetrahydrofolate in man. N Eng J Med 286:175, 1972
Main reference
Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:1030, calcium glycerinophosphate
Main reference
Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:837, calcium trisodium penetate
Main references
Ginn HE, Anderson KE, Mercier RK, Stevens TW, Matter BJ: Camphor intoxication treated by lipid dialysis. JAMA 203:230, 1968
Jacobziner H, Raybin HW: Camphor poisoning. Arch Pediatr 79:28, 1962
Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:1552, camphor
Main references
Brogden RN, Todd PA, Sorkin EM: Captopril — an uptdate of its pharmacodynamic and pharmacokinetic properties and therapeutic use in hypertension and congestive heart failure. Drugs 36:540, 1988
Campbell BC, Shepherd AN, Elliot HL, McLean K, Reid JL: Prolonged converting enzyme inhibition following captopril in patients with renal insufficiency. Br J Clin Pharmacol 12:755, 1982
Case DB, Atlas SA, Mouradian JA, Fishman RA, Sherman RL, Laragh JH: Proteinuria during long-term captopril therapy. JAMA 244:346, 1980
Duchin KL, Singhvi SM, Willard DA, Migdalof BH, McKinstry DN: Captopril kinetics. Clin Pharmacol Ther 31:452, 1982
Duchin KL, Pierides AM, Heald A, Singhvi SM, Rommel AJ: Elimination kinetics of captopril in patients with renal failure. Kidney Int 25:942, 1984
Hays R, Aquino A, Lee BB, Lo R, Currier CB jr: Captopril-induced acute renal failure in a kidney transplant recipient. Clin Nephrol 19:320, 1983
Heel RC, Brogden RN, Speight TM, Avery GS: Captopril: A preliminary review of its pharmacological properties and therapeutic efficacy. Drugs 20:409, 1980
Hirakata H, Onoyama K, Iseki K, Omae T, Fujimi S, Kawahara Y: Captopril (SO 14225) clearance during hemodialysis treatment. Clin Nephrol 16:321, 1981
Hoorntje SJ, Kallenberg CG, Weening JJ et al.: Immune-complex glomerulopathy in patients treated with captopril. Lancet I:1212, 1980
Johnston CI: Handbook of hypertension vol. 5. Amsterdam, New York: Elsevier Science Publishers, 1984 p 272
Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:468, captopril
Pessina AC, Semplicini A, Rossi G et al.: Effects of captopril on renal function in hypertensive patients. Am J Cardiol 49:1572, 1980
Ram CVS: Captopril. Arch Intern Med 142:914, 1982
Report from the Captopril Collaborative Study Group: Does Captopril cause renal damage in hypertensive patients? Lancet I:988, 1982
Rommel AJ, Pierides AM, Heald A: Captopril elimination in chronic renal failure. Clin Pharmacol Ther 27:282, 1980
Sturgill BC, Shearlock KT: Membranous glomerulopathy and nephrotic syndrome after captopril therapy. JAMA 250:2343, 1983
Textor SC, Bravo E, Fouad FM et al.: Hyperkalemia in azotemic patients during angiotensin-converting enzyme inhibition and aldosterone reduction with captopril. Am J Med 73:719, 1982
Vidt DG, Bravo EL, Fouad FM: Captopril. N Engl J Med 306:214, 1982
Warren SE, O’Connor DT: Hyperkalemia resulting from captopril administration. JAMA 244:2551, 1980
Yeung JHK, Breckenridge AM, Park BK: Drug-protein conjugates. IV. The effect of acute renal failure on the disposition of (14C) captopril in the rat. Biochem Pharmacol 32:2467, 1983
Main reference
Johnson G, Regardh CG: Clinical pharmacokinetics of β-adrenoreceptor blocking drugs. Clin Pharmacokinet 1: 233, 1976
Main reference
Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:1329, carbachol
Main references
Bertilsson L, Höjer B, Tybring G, Osterloh J, Rane A: Autoinduction of carbamazepine metabolism in children examined by a stable isotope technique. Clin Pharmacol Ther 27:83, 1980
Christian T, Dam M: Influence of phenobarbital and diphenylhydantoin on plasma carbamazepine levels in patients with epilepsy. Acta Neurol Scand 49:543, 1973
Cotter LM, Eadie MJ, Hooper WD, Lander CM, Smith GA, Tyrer JH: The pharmacokinetics of carbamazepine. Eur J Clin Pharmacol 12:451, 1977
Eichelbaum M, Kothe KW, Hoffman F, von Unruh GE: Kinetics and metabolism of carbamazepine during combined antiepileptic drug therapy. Clin Pharmacol Ther 26:366, 1979
Ghio L, Galato R, Giani M, Edefonti A, Appiani A, Piceni-Sereni L, Romeo A, Viani F: Efficacy and pharmacokinetics of carbamazepine (CBZ) in a child during haemodialysis. Electroencephalogr Clin Neurophysiol 55:2P, 1983
Gruska H, Beyer KH, Kubicki ST, Schneider H: Klinik, Toxikologie und Therapie einer schweren Carbamazepine-Vergiftung. Arch Toxicol 27:193, 1971
Hooper WD, Dubetz DK, Bochner F, Cotter LM, Smith GA, Eadie MJ, Tyrer JH: Plamsa protein binding of carbamazepine. Clin Pharmacol Ther 17:433, 1975
Lee CS, Wang LH, Marbury TC, Bruni J, Perchalski RJ: Hemodialysis clearance and total body elimination of carbamazepine during chronic hemodialysis. J Toxicol Clin Toxicol 17:429, 1980
Levy RH, Pitlick WH, Troupin AS, Green JR, Neal JM: Pharmacokinetics of carbamazepine in normal man. Clin Pharmacol Ther 17:657, 1975
Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:400, carbamazepine
Nicholls DP, Yasin M: Acute renal failure from carbamazepine. Br Med J 4:490, 1977
Perucca E, Richens A: Water intoxication produced by carbamazepine and its reversal by phenytoin. Br J Clin Pharmacol 9:302P, 1980
Pitlick WH, Levy RH, Troupin AS, Green JRJ: Pharmacokinetic model to describe self induced decreases in steady-state concentrations of carbamazepine. J Pharm Sci 65:462, 1976
Rane A, Höjer B, Wilson JT: Kinetics of carbamazepine and its 10,11-epoxide metabolite in children. Clin Pharmacol Ther 19:276, 1976
Rawlins D, Collste P, Bertilsson L, Palmer L: Distribution and elimination kinetics of carbamazepine in man. Eur J Clin Pharmacol 8:91, 1975
Richens A, Warrington S: When should plasma drug levels be monitored? Drugs 17:488, 1979
Sillanpää M: Carbamazepine. Pharmacology and clinical use. Acta Neurol Scand 64 (Suppl 88):5, 1981
Zarday Z, Soberman RJ: Carbamazepine in uremic neuropathy. Ann Intern Med 84:296, 1976
Main references
Bacq ZM, Derouaux G: La semicarbazone de l’adrenochrome. Sêm Hôp Paris 26: 3347, 1950
Fischer P, Lecomte J: Action des quinones et des produits d’oxydation de l’adrenalisme sur la coagulation sanguine. Intervention des groupes — SH. Arch Int Physiol 56: 223, 1949
Main references
Appel G: Acute interstitial nephritis associated with carbenicillin therapy. Arch Intern Med 138:1265, 1978
Bailey RR, Eastwood JB, Vaughan RB: The pharmacokinetics of an oral form of carbenicillin in patients with renal failure. Postgrad Med J 48:422, 1972
Cheigh JS: Drug administration in renal failure. Am J Med 62:555, 1977
Eastwood JB, Curtis JR: Carbenicillin administration in patients with severe renal failure. Br Med J 1:486, 1968
Hoffman TA, Cestero R, Bullock WE: Pharmacokinetics of carbenicillin in patients with hepatic and renal failure. J Infect Dis 122 (Suppl):S75, 1970
Johny M, Derrington AW, Lawrence JR: Carbenicillin therapy in renal failure. Med J Aust 2:681, 1969
Klastersky J, Vanderkelen B, Daneau D, Mathieu M: Carbenicillin and hypokalemia. Ann Intern Med 78:744, 1973
Latos DS, Bryan CS, Stone WJ: Carbenicillin therapy in patients with normal and impaired renal function. Clin Pharmacol Ther 17:692, 1975
Lipner HI, Ruzany F, Dasgupta M et al.: The behavior of carbenicillin as a nonresorbable anion. J Lab Clin Med 86:183, 1975
Lurie A, Ogilvie M, Townsend R, Gold C, Meyers AM, Goldberg B: Carbenicillin-induced coagulopathy. Lancet I:1114, 1970
Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:139, carbenicillin disodium
Nakano H, Sasaki K, Mizoguchi M et al.: Absorption and excretion of carbenicillin indanyl sodium in patients with reduced kidney function. Chemotherapy 23:299, 1977
Pancoast SJ, Neu HC: Kinetics of mezlocillin and carbenicillin. Clin Pharmacol Ther 24:108, 1978
Standiford HC, Jordan MC, Kirby WMM: Clinical pharmacology of carbenicillin compared with other penicillins. J Infect Dis 122 (Suppl):S9, 1970
Tabernero-Romo JM, Corbacho L, Sanchez S et al.: Effects of carbenicillin on blood coagulation: A study in patients with chronic renal failure. Clin Nephrol 11:31, 1979
Whelton A, Carter CG, Garth MA: Carbenicillin-induced acidosis and seizures. JAMA 218:1942, 1971
Whelton A, Carter CG, Bryant HH, Porteous LA, Walker WG: Carbenicillin concentrations in normal and diseased kidneys: A therapeutic consideration. Ann Intern Med 78:659, 1973
Zwelling IA, Balow JE: Hypersthenuria in high-dose carbenicillin therapy. Ann Intern Med 89:225, 1978
Main reference
Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:1080, carbonoxolone sodium
Main references
Johnson RD, Ruthven CR, Goodwin BL, Sandler M: In vivo assessment of decarboxylase inhibition or potentiation: Urinary dopamine and l-dopa output after l-dopa administration. J Neural Transm 38:181, 1976
Reid JL, Calne DB, Vakil SD, Allen JG, Davies CA: Plasma concentration of levodopa in parkinsonism before and after inhibition of peripheral decarboxylase. J Neurol Sci 17:45, 1972
Vickers S, Stuart EK, Bianchine JR et al.: Metabolism and carbidopa, an aromatic amino acid decarboxylase inhibitor in the rat, dog, rhesus monkey and man. Drug Metab Dispos 2:9, 1974
Main references
Benker G, Reinwein D: Pharmacokinetics of antithyroid drugs. Klin Wochenschr 60:531, 1982
Jansson R, Lindström B, Dahlberg PA: Pharmacokinetic properties and bioavailability of methimazole. Clin Pharmacokinet 10:443, 1985
Kampmann JP, Hansen JM: Clinical pharmacokinetics of antithyroid drugs. Clin Pharmacokinet 6:401, 1981
Melander A, Hallengren B, Rosendal-Helgesen S, Sjöberg AK, Wahlin-Boll E: Comparative in vitro effects and in vivo kinetics of antithyroid drugs. Eur J Clin Pharmacol 17:295, 1980
Skellern GG, Knight BI, Low CK, Alexander WD, McLarty DG, Kalk WJ: The pharmacokinetics of methimazole after oral administration of carbimazole and methimazole, in hyperthyroid patients. Br J Clin Pharmacol 9:137, 1980
Main references
Beale HD, Rawling FFA, Figley KD: Clistin maleate. A clinical appraisal of a new antihistaminic. J Allergy 25:521, 1954
Cockrell JL: Acute hallucinogenic reaction to carbinoxamine maleate. J Toxicol Clin Toxicol 25:161, 1987
Garat BR, Landa CR, Rossi Richeri OF, Tracchia RO: Clinical, chemical, and pharmacologic relationships of antihistamines. A study of a new synthetic antihistaminic, carbinoxamine maleate (Clistin Maleate). J Allergy 27:57, 1956
Main references
Martin YC, Wiegand RG: Metabolism and excretion of chromonar and its metabolite in dog and man. J Pharm Sci 59:1313, 1970
Schraven E, Nitz RE, Klarwein M: Blutspiegel, Verteilung in den Organen und Ausscheidung von Carbochromen bei Ratte, Hund und Mensch. Arzneimittelforschung (Drug Res) 20:1905, 1970
Main references
Alha AR: Debrominaton compounds of bromisoval and carbromal in poisoning. Ann Med Exp Fenn 41:95, 1963
Butler TC: The metabolic fate of carbromal (2-bromo-2-ethyl-butyrylurea). J Pharmacol Exp Ther 143:23, 1964
Drasch G, v. Meyer L, Engel J, Hauck G: Probleme des Zerfalls bromharnstoffhaltiger Tabletten. Dtsch Apotheker Ztg 118:1630, 1978
Grabensee B, Hofmann K, Jax W, Königshausen T, Schnurr E, Schröder E: Klinik und Therapie der Bromcarbamid-Vergiftung. Dtsch Med Wochenschr 97:1911, 1972
Impens E: Über die physiologische Wirkung eines bromhaltigen Hypnotikums, des Adalins. Med Klin 6(II): 1861, 1910
Merrill JP, Weller JM: Treatment of bromism with the artificial kidney. Ann Intern Med 37:186, 1952
Schwabe U: Jährlich 1000 Todesfälle durch rezeptfreie bromcar-bamid-haltige Schlafmittel in der Bundesrepublik? Dtsch Med Wochenschr 102:885, 1977
Seyffart G: Antihistamines and other sedatives. F. Ethinamate and other sedatives. In: Haadad LM and Winchester JF (eds): Clinical management of poisoning and drug overdose. Philadelphia: Saunders, 1990, chapter 46, p. 850
Main references General
Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:605, carmustine
Ray JE, Wade DN, Graham GG. Day RO: Pharmacokinetics of carprofen in plasma and synovial fluid. J Clin Pharmacol 19:635, 1979
Ray JE, Wade DN, Graham GG: Absorption and metabolism of (14C)carprofen in man. Clin Exp Pharmacol Physiol 6:175, 1979
Main references Renal damage
Abraham PA, Keane WF: Glomerular and interstitial disease induced by nonsteroidal anti-inflammatory drugs. Am J Nephrol 4:1, 1984
Carmichael J, Shankel SW: Effects of non-steroidal anti-inflammatory drugs on prostaglandins and renal function. Am J Med 78:992, 1985
Clive DM, Stoff JS: Renal syndromes associated with nonsteroidal anti-inflammatory drugs. N Engl J Med 310:563, 1984
Duggin GG: Mechanisms in the development of analgesic nephropathy. Kidney Int 18:553, 1980
Dunn MJ: Non-steroidal anti-inflammatory drugs and renal function. Annu Rev Med 35:411, 1984
Hart D, Lifschitz MD: Renal physiology of the prostaglandins and the effects of nonsteroidal anti-inflammatory agents on the kidney. Am J Nephrol 7:408, 1987
Henrich WL: Nephrotoxicity of nonsteroidal anti-inflammatory agents. Am J Kidney Dis 2:478, 1982
Orme ML’E: Non-steroidal anti-inflammatory drugs and the kidney. Br Med J 292:1521, 1986
Reeves WB, Foley RJ, Weinman EJ: Renal dysfunction from nonsteroidal anti-inflammatory drugs. Arch Intern Med 144:1943, 1984
Simon LS, Mills JA: Nonsteroidal antiinflammatory drugs (First of two parts). N Engl J Med 302:1179, 1980
Simon LS, Mills JA: Nonsteroidal antiinflammatory drugs (Second of two parts). N Engl J Med 302:1237, 1980
Torres VE: Present and future of non-steroidal anti-inflammatory drugs in nephrology. Mayo Clin Proc 57:389, 1982
Toto RD, Anderson SA, Brown-Cartwright D, Kokko JP, Brater DG: Effects of acute and chronic dosing of NSAIDs in patients with renal insufficiency. Kidney Int 30:760, 1986
Wegmüller E: Nicht-steroidale Antirheumatika und Nephrotoxi-zität. Dtsch Med Wochenschr 110:469, 1985
Main references
Hasenfuß G, Schäfer-Korting M, Knauf H, Mutschler E, Just H: Pharmacokinetics of Carteolol in relation to renal function. Eur J Clin Pharmacol 29:461, 1985
Knauf H, Schäfer-Korting M, Mutschler E: Pharmakokinetik und biologiche Wirkdauer von β-Rezeptorenblockern bei Niereninsuffizienz. Internist 22:616, 1981
Mori H, Kido M, Muralami N, Morita S, Kohri H, Nakagawa K: Metabolic fate of carteolol hydrochloride, 5-(3-tert-butyl-amino-2-hydroxy-propoxy)-3,4-dihydrocarbostyril hydrochloride, OPC-1085, a new β-blocker. V. Identification of metabolites in rat, dog and human. J Pharmaceut Soc Japan 97:350, 1977
Morita S, linuma M, Kido M, Sakuragi S, Kohri H, Nishino H: Metabolic fate of carteolol hydrochloride (OPC-1085), a new β-adrenergic blocking agent. VIII. Pharmacokinetic studies of carteolol in man. Arzneimittelforschung (Drug Res) 27(II):2380, 1977
Morita S, Irie Y, Sakuragi S, Kohri H, Nishino H: Metabolic fate of carteolol hydrochloride (OPC-1085), a new β-adrenergic blocking agent. VI. Pharmacokinetics of carteolol in rat, dog, rabbit and man. Folia Pharmacol Japon 73:299, 1977
Main references
Dominguez-Gil A, Castineiras MC, Tabernero JM, Rodriguiz Comenes JL, Castro S de: Pharmacokinetics of cephacetrile in patients with normal or impaired renal function. Eur J Clin Pharmacol 13:445, 1978
Dominguez-Gil A, Lanao JM, Tabernero JM, Rodriguiz Comenes JL, Castro S de: Pharmacokinetics of cephacetrile in patients undergoing hemodialysis. Eur J Clin Pharmacol 16:49, 1979
Spring P, Räber J, Reber H, Dettli L: Die Elimination des Antibiotikums Cephacetril bei Patienten mit eingeschränkter Nierenfunktion. Schweiz Med Wochenschr 103:783, 1973
Main references
Berman SJ, Boughton WH, Sugihara JJ, Wong EGC, Sato MM, Siemens AW: Pharmacokinetics of cefaclor in patients with end stage renal disease during hemodialysis. Antimicrob Agents Chemother 14:281, 1978
Bloch R, Szwed JJ, Sloan RS, Luft FC: Pharmacokinetics of cefaclor in normal subjects and patients with chronic renal failure. Antimicrob Agents Chemother 12:730, 1977
Fillastre J, Leroy A, Humber G, Godin M: Cefaclor pharmacokinetics and renal impairment. J Antimicrob Chemother 6:155, 1980
Goodman and Gilman’s The pharmacological basis of therapeutics. 7th ed. New York: Macmillan, 1985:1115, chapter 50, Antimicrobil agents by GL Mandell and MA Sande
Levison ME, Santoro J, Agarwal BN: In vitro activity and pharmacokinetics of cefaclor in normal volunteers and patients with renal failure. Postgrad Med J 55:12, 1979
Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:142, cefaclor.
Meyers BR, Hirschman SZ, Wormser G, Gartenberg G, Srulevippel E: Pharmacologic studies with cefaclor, a new oral cephalosporin. J Clin Pharmacol 18:174, 1978
Pommer W, Krause PH, Berg PA, Neumayer H H, Mihatsch MJ, Molzahn M: Acute interstitial nephritis and non-oliguric renal failure after cefaclor treatment. Klin Wochenschr 64:290, 1986
Santoro J, Agarwal BN, Martinelli R, Wenger N, Levison ME: Pharmacology of cefaclor in normal volunteers and patients with renal failure. Antimicrob Agents Chemother 13:951, 1978
Spyker DA, Gober LL, Scheld WM, Sande MA, Bolton WK: Pharmacokinetics of cefaclor in renal failure: Effects of multiple doses and hemodialysis. Antimicrob Agents Chemother 21:278, 1982
Main references
Cutler RE, Blair AD, Kelly MR: Cefadroxil kinetics in patients with renal insufficiency. Clin Pharmacol Ther 25:514, 1979
Ginsburg CM, McCracken GH jr, Clahsen JC, Thomas ML: Clinical pharmacology of cefadroxil in infants and children. Antimicrob Agents Chemother 13:845, 1978
Goodman and Gilman’s The pharmacological basis of therapeutics. 7th ed. New York: Macmillan, 1985:1115, chapter 50, Antimicrobial agents by GL Mandell and MA Sande
Humbert G, Leroy A, Fillastre J, Godin M: Pharmacokinetics of cefadroxil in normal subjects and in patients with renal insufficiency. Chemotherapy 25:189, 1979
Jolly ER, Henness DM, Richards D jr: Human safety tolerance and pharmacokinetic studies of cefadroxil, a new cephalosporin antibiotic for oral administration. Curr Ther Res 22:727, 1977
Pfeffer M, Jackson A, Ximenes J, De Menezes JP: Comparative human oral clinical pharmacology of cefadroxil, cephalexin, and cephadrine. Antimicrob Agents Chemother 11:331, 1977
Main references
Andriole VT: Pharmacokinetics of cephalosporins in patients with normal or reduced renal function. J Infect Dis 137 (Suppl): S88, 1978
Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:176, cefaloridine.
Nightingale CH, Greene DS, Quintiliani R: Pharmacokinetics and clinical use of cephalosporin antibiotics. J Pharm Sci 64:1899, 1975
Main references
Ahem MJ, Finkelstein FO, Andriole VT: Pharmacokinetics of cefamandole in patients undergoing hemodialysis and peritoneal dialysis. Antimicrob Agents Chemother 10:457, 1976
Appel GB, Neu HC, Parry MF, Goldberger MJ, Jacob GB: Pharmacokinetics of cefamandole in the presence of renal failure and in patients undergoing hemodialysis. Antimicrob Agents Chemother 10:623, 1976
Brogard JM, Kopferschmitt J, Spach MO, Grudet O, Lavillaureix J: Cefamandole pharmacokinetics and dosage adjustments in relation to renal function. J Clin Pharmacol 19:366, 1979
Campillo JA, Lanao JM, Dominguez-Gil A, Tabernero JM, Rubio F: Pharmacokinetics of cephamandole in patients undergoing hemodialysis. Int J Clin Pharmacol Biopharm 17:416, 1979
Czerwinski AW, Pederson JA: Pharmacokinetcs of cefamandole in patients with renal impairment. Antimicrob Agents Chemother 15:161, 1979
Gambertoglio JG, Aziz NS, Lin ET, Grausz H, Naughton JL, Benet LZ: Cefamandole kinetics in uremic patients undergoing hemodialysis. Clin Pharmacol Ther 26:592, 1979
Goodman and Gilman’s The pharmacological basis of therapeutics. 7th ed. New York: Macmillan, 1985:1115, chapter 50, Antimicrobial agents by GL Mandell and MA Sande
Janicke DM, Morse GD, Apicella M, Jusko WJ, Walshe JJ: Pharmacokinetic modeling of bidirectional transfer during peritoneal dialysis. Clin Pharmacol Ther 40:209, 1986
Martindale. The extra pharmacopeia. 29th ed. London: The Pharmaceutical Press, 1989:179, cefamandole
McAllister TA, Mocan H, Murphy AV, Beattie TJ: Antibiotic susceptibility of staphylococci from CAPD peritonitis in children. J Antimicrob Chemother 19:95, 1987
Morse GD, Rowinski C, Lieveld PE, Walshe JJ: Drug-protein binding during continuous ambulatory peritoneal dialysis. Perit Dial Bull 6:144, 1986
Neu H: Comparison of the pharmacokinetics of cefamandole and other cephalosporin compounds. J Infect Dis 137:580, 1978
Pancorbo S, Comty C: Pharmacokinetics of cefamandole in patients undergoing continuous ambulatory peritoneal dialysis. Perit Dial Bull 3:135, 1983
Scott DK, Roberts DE: Drugs and continuous peritoneal dialysis (Part 2). Pharm J 234:621, 1985
Main references
Lange H, Dapper FD, Baier R: Pharmakokinetik und Dosierung von Cefazedon bei Dialysepatienten. Klinikarzt 11:409, 1982
Pabst J, Leopold G, Ungethüm W, Dingeldein E: Clinical pharmacology phase 1 of cefazedone, a new cephalosporin, in healthy volunteers. II. Pharmacokinetics in comparison with cefazolin. Arzneimittelforschung (Drug Res) 29(I):437, 1979
Ungethüm W, Pabst J, Dingeldein E, Leopold G: Clinical pharmacology phase 1 of cefazedone, a new cephalosporin in healthy volunteers. III. Investigations of the mechanism of renal elimination. Arzneimittelforschung (Drug Res) 29(0:443, 1979
Main references
Brogard JM, Pinget M, Brandt C, Lavillaureix J: Pharmacokinetics of cefazolin in patients with renal failure: special reference to hemodialysis. J Clin Pharmacol 17:225, 1977
Bunke CM, Aronoff GR, Brier ME, Sloan RS, Luft FC: Cefazolin and cephalexin kinetics in continuous ambulatory peritoneal dialysis. Clin Pharmacol Ther 33:66, 1983
Craig CP, Rifkin SI: Pharmacokinetics and hemodialyzability of cefazolin in uremic patients. Clin Pharmacol Ther 19:825, 1976
Craig WA, Welling PG, Jackson TC, Kunin CM: Pharmacology of cefazolin and other cephalosporins in patients with renal insufficiency. J Infect Dis 128 (Suppl):S347, 1973
Czerwinski AW, Pederson JA, Barry JP: Cefazolin plasma concentrations and urinary excretion in patients with renal impairment. J Clin Pharmacol 14:560, 1974
Eastwood JB, Gower PE, Curtis JR: The serum half-life and urine concentration of cefazolin sodium in patients with terminal renal failure: Effect of haemodialysis. Scoff Med J 20:240, 1975
Greene DS, Tice AD: Effect of hemodialysis on cefazolin protein binding. J Pharm Sci 66:1508, 1977
Hiner LB, Baluarte HJ, Polinsky MS, Gruskin AB: Cefazolin in children with renal insufficiency. J Pediatr 96:335, 1980
Kaye D, Wenger N, Agarwal B: Pharmacology of intraperitoneal cefazolin in patients undergoing peritoneal dialysis. Antimicrob Agents Chemother 14:318, 1978
Kirby WMM, Regamey C: Pharmacokinetics of cefazolin compared with four other cephalosporins. J Infect Dis 128 (Suppl):S341, 1973
Levison ME, Levison SP, Ries K, Kaye D: Pharmacology of cefazolin in patients with normal and abnormal renal function. J Infect Dis 128 (Suppl):S354, 1973
Madhavan T, Yaremchuk K, Levin N, Fisher E, Cox F, Burch K, Haas E, Pohlod D, Quinn EL: Effects of renal failure and dialysis on cefazolin pharmacokinetics. Antimicrob Agents Chemother 8:63, 1975
McCloskey RV, Forland MF, Sweeney MJ, Lawrence DN: Hemodialysis of cefazolin. J Infect Dis 128 (Suppl):S358, 1973
Quintiliani R, Nightingale CH: Cefazolin. Ann Intern Med 89 (Part 1):650, 1978
Rein MF, Westervelt FB, Sande MA: Pharmacodynamics of cefazolin in the presence of normal and impaired renal function. Antimicrob Agents Chemother 4:366, 1973
Sack K, Wilhelm J: Klinische Verlaufsstudie zur Nierenträglichkeit von Cefazolin. Infection 2 (Suppl 1):68, 1974
Welling PG, Craig WA, Amidon GL, Kunin CM: Pharmacokinetics of cefazolin in normal and uremic subjects. Clin Pharmacol Ther 15:344, 1974
Main reference
Guay DRP, Meatherall RC, Harding GK, Brown GR: Pharmacokinetics of cefixime (CL 284, 635, FK 027) in healthy subjects and patients with renal insufficiency. Antimicrob Agents Chemother 30:485, 1986
Main references
Gambertoglio JG, Alexander DP, Barriere SL: Cefmenoxime pharmacokinetics in healthy volunteers and subjects with renal isufficiency and on hemodialysis. Antimicrob Agents Chemother 26:845, 1984
Polk RE, Sica DA, Kerkering TM, Kline BJ, Patterson PM, Baggett JW: Cefmenoxime pharmacokinetics in patients with renal insufficiency. Antimicrob Agents Chemother 26:322, 1984
Sica DA, Polk RE, Kerkering TM, Patterson PM, Baggett JW: Cefmenoxime kinetics during continuous ambulatory peritoneal dialysis. Eur J Clin Pharmacol 30:713, 1986
Main references
Barriere SL, Gambertoglio JG, Alexander DP, Stagg RJ, Conte JE jr: Pharmacokinetic disposition of cefonicid in patients with renal failure and receiving hemodialysis. Rev Infect Dis 6 (Suppl 4):S809, 1984
Blair AD, Maxwell BM, Forland SC, Jacob L, Cutler RE: Cefonicid kinetics in subjects with normal and impaired renal function. Clin Pharmacol Ther 35:798, 1984
Goodman and Gilman’s The pharmacological basis of therapeutics. 7th ed. New York: Macmillan, 1985:1115, chapter 50. Antimicrobial agents by GL Mandell and MA Sande
Morse GD, Lane T, Nairn DK, Deterding J, Curry J, Gal P: Peritoneal transport of cefonicid. Antimicrob Agents Chemother 31:292, 1987
Phelps RT, Conte JE: Multiple-dose pharmacokinetics of cefonicid in patients with impaired renal function. Antimicrob Agents Chemother 29:913, 1986
Pitkin D, Dubb J, Actor P, Alexander F, Ehrlich S, Familiar R, Stote R: Kinetics and renal handling of cefonicid. Clin Pharmacol Ther 30:587, 1981
Main references
Allaz AF, Dayer P, Fabre J, Rudhardt M, Balant L: Pharmaco-cinetique d’une nouvelle cephalosporine, la cefoperazone. Schweiz Med Wochenschr 109:1999, 1979
Bolton WK, Scheld WM, Spyker DA, Sande MA: Pharmacokinetics of cefoperazone in normal volunteers and subjects with renal insufficiency. Antimicrob Agents Chemother 19:821, 1981
Greenfield RA, Gerber AU, Craig WA: Pharmacokinetics of cefoperazone in patients with normal and impaired hepatic and renal function. Rev Infect Dis 5 (Suppl):S127, 1983
Hodler JE, Galeazzi RL, Frey B, Rudhardt M, Seiler AJ: Pharmacokinetics of cefoperazone in patients undergoing chronic ambulatory peritoneal dialysis: Clinical and pathophysiological implications. Eur J Clin Pharmacol 26:609, 1984
Jendroschek T, Belmega G, Lode H, Kemmerich B, Dzwillo G, Koeppe P, Wagner J: Ein neues Breitband-Antibiotikum. Med Klin 76:102, 1981
Keller E, Jansen A, Pelz K, Hoppe-Seyler G, Schollmeyer P: Intraperitoneal and intravenous cefoperazone kinetics during continuous ambulatory peritoneal dialysis. Clin Pharmacol Ther 35:208, 1984
Spyker DA, Richmond JD, Scheld WM, Bolton WK: Pharmacokinetics of multiple-dose cefoperazone in hemodialysis patients. Am J Nephrol 5:355, 1985
Trollfors B, Ahlem J, Alestig K: Renal function during cefoperazone treatment. J Antimicrob Chemother 9:485, 1982
Main references
Estey EH, Weaver SS, LeBlanc BM, Brown N, Ho DH, Bodey GP: Ceforanide kinetics. Clin Pharmacol Ther 30:398, 1981
Hawkins SS, Alford RH, Stone WJ, Smyth RD, Pfeffer M: Ceforanide kinetics in renal insufficiency. Clin Pharmacol Ther 30:468, 1981
Hess JR, Berman SJ, Boughton WH, Sugihara JG, Musgrave JE, Wong EGC, Siemens AM: Pharmacokinetics of ceforanide in patients with end stage renal disease on hemodialysis. Antimicrob Agents Chemother 17:251, 1980
Lanao JM, De Prada CR, Dominguez-Gil A, Tabernero JM, Martin J, Gomez JR: Ceforanide pharmacokinetics in haemodialysis: The effect of ultrafiltration. Biopharm Drug Dispos 7:335, 1986
Main references
Albin HC, Demotes-Mainard FM, Bouchet JL, Vincon GA, Martin-Dupont C: Pharmacokinetics of intravenous and intraperitoneal cefotaxime in chronic ambulatory peritoneal dialysis. Clin Pharmacol Ther 38:285, 1985
Baier R, Furkert D, Frei M, Dapper D, Lange H: Pharmakokinetik von Cefotaxim bei Patienten unter chronischer Hämodialyse-behandlung. Nieren- und Hochdruckkrankh 12:114, 1983
Chodos J, Francke EL, Saltzman M, Neu HC: Pharmacokinetics of intravenous cefotaxime in patients undergoing chronic hemodialysis. Ther Drug Monit 3:71, 1981
Doluisio JT; Clinical pharmacokinetics of cefotaxime in patients with normal and impaired renal function. Rev Infect Dis 4 (Suppl): S333, 1982
Fu UP, Aswapokee P, Ho I, Matthijssen C, Neu HC: Pharmacokinetics of cefotaxime. Antimicrob Agents Chemother 16:592, 1979
Heim KL, Halstenson CE, Comty CM, Affrime MB, Matzke GR: Disposition of cefotaxime and desacetyl cefotaxime during continuous ambulatory peritoneal dialysis. Antimicrob Agents Chemother 30:15, 1986
Ings RM, Fillastre JP, Godin M, Leroy A, Humbert G: The pharmacokinetics of cefotaxime and its metabolites in subjects with normal and impaired renal fuction. Rev Infect Dis 4 (Suppl):S379, 1982
Glöckner WM, Kindler J, Höffer U, Peters G, Siebert HG: Pharmakokinetik von Cefotaxim bei Patienten mit dialysepflichtiger Niereninsuffizienz. Infection 8:S430, 1980
Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:151, cefotaxime sodium
Matzke GR, Abraham PA, Halstenson CE, Keane WF: Cefotaxime and desacetyl cefotaxime kinetics in renal impairment. Clin Pharmacol Ther 38:31. 1985
Ohkawa M, Okasho A, Motoi I, Tokunaga S, Shoda R, Kawaguchi S, Sawaki M, Shimamura M, Hirano S, Kuroda K, Awazu S: Elimination kinetics of cefotaxime and desacetyl cefotaxime in patients with renal insufficiency and during hemodialysis. Chemotherapy 29:4, 1983
Petersen J, Stewart RD, Catto GR, Edward N: Pharmacokinetics of intraperitoneal cefotaxime treatment of peritonitis in parients on continuous ambulatory peritoneal dialysis. Nephron 40:79, 1985
Wise R, Wright N, Wills PJ: Pharmacology of cefotaxime and its desacetyl metabolite in renal and hepatic disease. Antimicrob Agents Chemother 19:526, 1981
Main references
Browning M, Chapman S, Cockshott ID, White L, Yates RA: Pharmacokinetics of cefotetan in patients requiring chronic ambulatory peritoneal dialysis. In: Lode H, Periti P, Strachan CJ, (eds): Cefotetan: A long-acting antibiotic. Edinburgh: Churchill Livingstone, 1985 p 106
Martindale. The extra pharmacopoeia. 29th ed. London: The Phrmaceutical Press. 1989:156, cefotetan disodium
Ohkawa M, Hirano S, Tokunaga S, et al.: Pharmacokinetics of cefotetan in normal subjects and patients with impaired renal function. Antimicrob Agents Chemother 23:31, 1983
Smith BR, LeFrock JL, Thyrum PT, Doret BA, Yeh C, Onesti G, Schwartz A, Zimmerman JJ: Cefotetan pharmacokinetics in volunteers with various degrees of renal function. Antimicrob Agents Chemother 29:887, 1986
Ward A, Richards DM: Cefotetan: a review of its antimicrobial activity, pharmacokinetic properties and therapeutic uses. Drugs 30:382, 1985
Main references
Alonso IG, Matino EL, Dominguez-Gil A, Tabernero JM: Pharmacokinetics of cefotiam during hemofiltration. Int J Clin Pharmacol Ther Toxicol 24:359, 1986
Konishi K, Ozawa Y: Pharmacokinetics of cefotiam in patients with impaired renal function and in those undergoing hemodialysis. Antimicrob Agents Chemother 26:647, 1984
Lecaillon JB, Rouan MC, Binswanger U, Guibert J, Schoeller JP: Pharmacokinetics of cefotiam and cefsulodin after simultaneous administration to patients with impaired renal function. Antimicrob Agents Chemother 26:368, 1984
Rouan MC, Binswanger U, Bammatter F, Theobaldt W, Schoeller JP, Guibert J: Pharmacokinetics and dosage adjustment of cefotiam in renal impaired patients. J. Antimicrob Chemother 19:611, 1984
Main references
Arvidsson A, Alvan G, Tranaeus A, Malmborg AS: Pharmacokinetic studies of cefoxitin in continuous ambulatory peritoneal dialysis. Eur J Clin Pharmacol 28:333, 1985
Brogden RN, Heel RC, Speight TM, Avery GS: Cefoxitin: A review of its antibacterial activity, pharmacological properties and therapeutic use. Drugs 17:1, 1979
Fillastre JP, Leroy A, Godin M, Oksenhendler G, Humbert G: Pharmacokinetics of cefoxitin sodium in normal subjects and in uraemic patients. J Antimicrob Chemother 4(B):79, 1978
Garcia MJ, Dominguez-Gil A, Tabernero JM, Tomero JAS: Pharmacokinetics of cefoxitin in patients with normal and impaired renal function. Eur J Clin Pharmacol 16:119, 1979
Garcia MJ, Dominguez-Gil A, Tabernero JM, Bondia Roman A: Pharmacokinetics of cefoxitin in patients undergoing hemodialysis. Int J Clin Pharmacol Biopharm 17:366, 1979
Garcia MJ, Dominguez-Gil A, Tabernero JM, Diaz Molina M: Pharmacokinetics of cefoxitin during haemofiltration. Eur J Clin Pharmacol 25:395, 1983
Greaves WL, Kreeft JH, Ogilvie RI, Richards GK: Cefoxitin disposition during peritoneal dialysis. Antimicrob Agents Chemother 19:253, 1981
Humbert G, Fillastre JP, Leroy A, Godin M, Van Winzum C: Pharmacokinetics of cefoxitin in normal subjects and in patients with renal insufficiency. Rev Infect Dis 1:118, 1979
Lange H, Puppel H, Trost G: Pharmakokinetik von Cefoxitin unter Dialysebehandlung. Infection 7 (Suppl 1):S76, 1979
Saah AJ, Koch TR, Drusano GL; Cefoxitin falsely elevates creatinine levels. JAMA 247:205, 1982
Schrogie J, Davies R, Yeh K et al.: Bioavailability and pharmacokinetics of cefoxitin sodium. J Antimicrob Chemother 4(B):69, 1978
Vlasses PH, D’Silva H, Rocci ML jr, Koplin JR, Bland JA, Sici-liano EG, Ferguson RK: Disposition of intravenous and intraperitoneal cefoxitin during chronic intermittent peritoneal dialysis. Am J Kidney Dis 3:67, 1983
Wise R, Donovan IA, Ambrose NS, Allcock JE: The penetration of cefoxitin into peritoneal fluid. J Antimicrob Chemother 8:453, 1981
Main references
Bergan T, Brodwall EK, Larsen EW: Relationship between pharmacokinetics and bioavailability of cefroxadine (CGP 9000) and renal function. Chemotherapy 29:163, 1983
Nieto MJ, Lanao JM, Dominguez-Gil A, Tabernero JM, Macias JF: Elimination of cefroxadine (CGP-9000) from patients indergoing dialysis. Eur J Clin Pharmacol 24:109, 1983
Ohkawa M, Takamae K, Shimamura M et al.: Pharmacokinetics of cefroxadine in healthy volunteers and patients with impaired renal function. Chemotherapy 27:149, 1981
Main references
Gibson TP, Granneman GR, Kallal JE, Sennello LT: Cefsulodin kinetics in renal impairment. Clin Pharmacol Ther 31:602, 1982
Gillespie WR, Veng-Pedersen P, Gibson TP: Deconvolution applied to the kinetics of extracorporal drug removal. Hemodialysis of cefsulodin. Eur J Clin Pharmacol 29:503, 1985
Granneman GR, Sennello LT, Sonders RC, Wynne B, Thomas EW: Cefsulodin kinetics in healthy subjects after intramuscular and intravenous injection. Clin Pharmacol Ther 31:95, 1982
Matzke GR, Keane WF: Cefsulodin pharmacokinetics during hemodialysis. Trans Am Soc Artif Intern Organs 28:324, 1982
Main references
Ackerman BH, Ross J, Tofte RW, Rotschafer JC: Effect of decreased renal function on the pharmacokinetics of ceftazidime. Antimicrob Agents Chemother 25:785, 1984
Leroy A, Leguy F, Borsa F, Spencer GR, Fillastre JP, Humber G: Pharmacokinetics of ceftazidime in normal and uremic subjects. Antimicrob Agents Chemother 25:638, 1984
Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:162, ceftazidime.
Nikolaidis P, Tourkantonis A: Effect of hemodialysis on ceftazidime pharmacokinetics. Clin Nephrol 24:142, 1985
Tourkantonis A, Nikolaidis P: Pharmacokinetics of ceftazidime in patients undergoing peritoneal dialysis. J Antimicrob Chemother 12 (Suppl A):263,1983
Van Dalen R, Vree TB, Baars AM, Termond E: Dosage adjustment for ceftazidime in patients with impaired renal function. Eur J Clin Pharmacol 30:597, 1986
Main references
Burgess ED, Blair AD: Pharmacokinetics of ceftizoxime in patients undergoing continuous ambulatory peritoneal dialysis. Antimicrob Agents Chemother 24:237, 1983
Dubb J, Actor P, Pirkin D et al.: Ceftizoxime kinetics and renal handling. Clin Pharmaco Ther 31:516, 1982
Gross ML, Somani P, Ribner BS, Raeader R, Freimer EH, Higgins JT jr: Ceftizoxime elimination kinetics in continuous ambulatory peritoneal dialysis. Clin Pharmacol Ther 34:673, 1983
Johnson CA, Zimmerman SW, Bayer W, Craig WA: Pharmacokinetics of intravenous ceftizoxime in patients in continuous ambulatory peritoneal dialysis. Clin Nephrol 23:120, 1985
Kowalsky SF, Echols RM, Venezia AR, Andrews EA: Pharmacokinetics of ceftizoxime in subjects with various degrees of renal function. Antimicrob Agents Chemother 24:151, 1983
Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:166, ceftizoxime sodium
Ohkawa M, Okasho A, Sugata T et al.: Elimination kinetics of ceftizoxime in humans with and without renal insufficiency. Antimicrob Agents Chemother 22:308, 1982
Shah PM, Knobloch M, Haag R, Kühnle HF: Pharmacokinetics of ceftizoxime in patients undergoing hemodialysis. Methods Find Exp Clin Pharmacol 4:185, 1982
Main reference
Albin H, Ragnaud JM, Demotes-Mainard F, Vincon G, Couzineau M, Wone C: Pharmacokinetics of intravenous and intraperitoneal ceftriaxone in chronic ambulatory peritoneal dialysis. Eur J Clin Pharmacol 31:479, 1986
Cohen D, Appel GB, Scully B, Neu HC: Pharmacokinetics of ceftriaxone in patients with renal failure and in those undergoing hemodialysis. Antimicrob Agents Chemother 24:529, 1983
Koup JR, Keller E, Neumann H, Stoeckel K: Ceftriaxone pharmacokinetics during peritoneal dialysis. Eur J Clin Pharmacol 30:303, 1986
Patel IH, Sugihara JG, Weinfeld RE, Wong EGC, Siemsen AW, Berman SJ: Ceftriaxone pharmacokinetics in patients with various degrees of renal impairment. Antimicrob Agents Chemother 25:438, 1984
Stoeckel K, McNamara PJ, Hoppe-Seyler G, Blumberg A, Keller E: Single-dose ceftriaxone kinetics in functionally anephric patients. Clin Pharmacol Ther 33:633, 1983
Stoeckel K, Koup JR: Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein binding model. Am J Med 77(4c):26, 1984
Ti TY, Fortin L, Kreeft JH, East DS, Ogilvie RI, Somerville PJ: Kinetic disposition of intravenous ceftriaxone in normal subjects and patients with renal failure on hemodialysis or peritoneal dialysis. Antimicrob Agents Chemother 25:83, 1984
Main references
Brown G: Die Pharmakokinetik von Cefuroxim-Axetil. Fortschr Antimikrob Antineoplast Chemother 6-8:1319, 1987
Bundtzen RW, Toothaker RD, Nielson OS, Madsen PO, Welling PG, Craig WA: Pharmacokinetics of cefuroxime in normal and impaired renal function: Comparison of high-pressure liquid chromatography and microbiological assays. Antimicrob Agents Chemother 19:443, 1981
Chan MK, Browning AK, Poole CJ, Matheson LA. Li CS, Baillod, RA: Cefuroxime pharmacokinetics in continuous and intermittent peritoneal dialysis. Nephron 41:161, 1985
Cox CE, Sherrill JM, Cocchetto DM: Evaluation of cefuroxime axetil, cefaclor and cephalexin in the treatment of urinary tract infections in adults. Curr Ther Res 42:124, 1987
van Dalen R, Vree TB, Hafkenscheid JC, Gimbrere JS: Determination of plasma and renal clearance of cefuroxime and its pharmacokinetics in renal insufficiency. J Antimicrob Chemother 5:281, 1979
Foord RD: Cefuroxime: Human pharmacokinetics. Antimicrob Agents Chemother 9:741, 1976
Gower PE, Dash CM: The pharmacokinetics of cefuroxime after intravenous injection. Eur J Clin Pharmacol 12:221, 1977
Harding SM, Williams Peo, Ayrton J: Pharmacology of cefuroxime as the 1-acetoxyethyl ester in volunteers. Antimicrob Agents Chemother 25: 78, 1984
Kosmidis J, Stathakis C, Anyfantis A, Daikos GK: Cefuroxime in renal insufficiency: Therapeutic results in various infections and pharmacokinetics including the effect of dialysis. Proc Roy Soc Med 70 (Suppl 9): 139, 1977
LaGreca G, Biasioli S, Chiaramonte S, et al.: Pharmacokinetics of intravenous and intraperitoneal cefuroxime during peritoneal dialysis. Int J Clin Pharmacol Ther Toxicol 20:92, 1982
Local FK, Munro AJ, Kerr DNS, Sussman M: Pharmacokinetics of intravenous and intraperitoneal cefuroxime in patients undergoing peritoneal dialysis. Clin Nephrol 16:40, 1981
Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:170, cefuroxime axetil
Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:171, cefuroxime sodium
Marx MA, Fant WK: Cefuroxime axetil. Drug Intel Clin Pharm 22:651, 1988
Neu HC, Fu KP: Cefuroxime, a beta-lactamase resistent cephalosporin with a broad spectrum of Grampositive and Gramnegative activity. Antimicrob Agents Chemother 13:657, 1978
Sommers DK, van Wyk MV, Williams PEO, Harding SM: Pharmacokinetics and tolerance of cefuroxime axetil in volunteers during repeated dosing. Antimicrob Agents Chemother 25:344, 1984
Trollfors B, Suurkula M, Price JD, Norrby R: Renal function during cefuroxime treatment in patients with pre-existing renal impairment. J Antimicrob Chemother 6:665, 1980
Walstad RA, Nilsen DG, Berg KJ: Pharmacokinetics and clinical effects of cefuroxime in patients with severe renal insufficiency. Eur J Clin Pharmacol 24:391, 1983
Wise R, Bennett SA, Dent J: The pharmacokinetics of orally absorbed cefuroxime compared with amoxycillin/clavulanic acid. J Antimicrob Chemother 13:603, 1984
Main references
Caruso FS, Doshan HD, Hernandez PH, Costello R, Applin W, Neiss ES: Celiprolol: Pharmacokinetics and duration of pharmacodynamic activity. Br J Clin Pract 39 (Suppl 40): 12, 1985
Hitzenberger G, Takacs F, Pittner H: Pharmakokinetik des Beta-Rezeptorenblockers Celiprolol nach einmaliger intravenöser und oraler Gabe am Menschen. Arzneimittelforschung (Drug Res) 33:50, 1983
Schmidt P, Takacs F, Pittner H, Minar E, Balcke P, Zazgornik J, Deutsch E: Vergleichende Pharmakokinetik des Beta 1-Rezeptoren-Blockers Celiprolol nach oraler Einzelgabe an Nierengesunde und an Patienten mit eingeschränkter Nierenfunktion. Wien Klin Wochenschr 97:729, 1985
Main references
Bailey RR, Gower PE, Dash CH: The effect of impairment of renal function and haemodialysis on serum and urine levels of cephalexin. Postgrad Med J 46 (Suppl September):60, 1970
Brogard JM, Pinget M, Dorner M, Lavillaureix J: Determination of cefalexin pharmacokinetics and dosage adjustment in relation to renal function. J Clin Pharmacol 15:666, 1975
Bunke CM, Aronoff GR, Brier ME, Sloan RS, Luft FC: Cefazolin and cephalexin kinetics in continuous ambulatory peritoneal dialysis. Clin Pharmacol Ther 33:66, 1983
Butcher RH, Dawborn JK, Pattison G: Blood and urine levels of cephalexin in patients with impaired renal function. Med J Aust 2:1282, 1972
Drew PJT, Casewell MW, Desai N, Houang ET, Simpson CN, Marsh FP: Cephalexin for the oral treatment of CAPD peritonitis. J Antimicrob Chemother 13:153, 1984
Griffith RS: The pharmacology of cephalexin. Postgrad Med J 59 (Suppl 5): 16, 1983
Hori R, Okumura K, Kamiya A, Nihira H, Nakano H: Ampicillin and cephalexin in renal insufficiency. Clin Pharmacol Ther 34:792, 1983
Kabins SA, Kelner B, Walton E et al.: Cephalexin therapy as related to renal function. Am J Med Sci 259:133, 1970
Kunin CM, Finkelberg Z: Oral cephalexin and ampicillin: Antimicrobial activity, recovery in urine, and persistence in blood of uremic patients. Ann Intern Med 72:349, 1970
Linquist JA, Siddiqui JY, Smith JM: Cephalexin in patients with renal disease. N Engl J Med 283:720, 1970
Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:173, cephalexin.
Regamey C, Hamair L: Pharmacokinetics of cephalexin in renal insufficiency. Postgrad Med J 47 (Febr Suppl):69, 1971
Reisberg BE, Mandelbaum JM: Cephalexin: absorption and excretion as related to renal function and hemodialysis. Infect Immun 3:540, 1971
Sennesael J, Verbeelen D, Lauwers S: Ototoxicity associated with cephalexin in two patients with renal failure. Lancet II: 1154, 1982
Main references
Burton JR, Lichtenstein NS, Colvin RB et al.: Acute renal failure during cephalothin therapy. JAMA 229:679, 1974
Höffler D, Koeppe P, Fuchs E, Fiegel P: Cephalotin-Plasmaspiegel bei normaler und eingeschränkter Nierenfunktion. Int J Clin Pharmacol Ther Toxicol 5(4):450, 1972
Kabins SA, Cohen S: Cephalotin serum levels in the azotemic patient. Antimicrob Agents Chemother 4:207, 1964
Kirby WMM, DeMaine JB, Serrill WS: Pharmacokinetics of the cephalosporins in healthy volunteers and uremic patients. Postgrad Med J 47 (Suppl Febr):41, 1971
Kunin CM, Atuk N: Excretion of cephaloridine and cephalothin in patients with renal impairment. N Engl J Med 274:654, 1966
Münch R, Steurer J, Lüthy R, Siegenthaler W, Kuhlmann U: Serum and dialyzate concentrations of intraperitoneal cephalothin in patients undergoing continuous ambulatory peritoneal dialysis. Clin Nephrol 20:40, 1983
Pasternak DP, Stephens BG: Reversible nephrotoxicity associated with cephalothin therapy. Arch Intern Med 135:599, 1975
Perkins RL, Smith EJ, Saslaw S: Cephalothin and cephaloridine: Comparative pharmacodynamics in chronic uremia. Am J Med Sci 257:116, 1969
Pickering MJ, Spooner GR, De Quesade A et al.: Declining renal function associated with administration of cephalothin. South Med J 63:426, 1970
Rankin L, Swain R, Luft F: Effect of cephalothin on measurement of creatinine concentration. Antimicrob Agents Chemother 15:666, 1979
Sanders WE jr, Johnson JE III, Taggart JG: Adverse reactions to cephalothin and cephapirin: Uniform occurrence on prolonged intravenous administration of high doses. N Engl J Med 290:424. 1974
Schulte-Lippern M, Freyland MD, Frotscher U, Jenett G, Messerschmidt W, Richter R, Zschaege B, Wilbrand R: Akutes Nierenversagen nach hochdosierter Cephalotinbehandlung. Med Klin 68:202, 1973
Spyker DA, Thomas BL, Sande MA, Bolton WK: Pharmacokinetics of cefaclor and cephalexin. Dosage nomograms for impaired renal function. Antimicrob Agents Chemother 14:172, 1978
Tourkantonis A, Mössner G, Egetmeyer KA, Heinze V: Cephalotin concentration during haemo- and peritoneal dialysis. Proc Eur Dial Transplant Assoc 5:353, 1969
Venuto RC, Plaut M: Cephalothin handling in patients undergoing hemodialysis. Antimicrob Agents Chemother 10:50, 1970
Wilson FM, Retan JW, Lerner AM: Clinical studies with cephalothin. J Urol 96:534, 1966
Main references
Arvidsson A, Borga D, Alvan G: Renal excretion of cephapirin and cephaloridine: Evidence for saturable tubular reabsorption. Clin Pharmacol Ther 25:870, 1979
Axelrod J, Meyers BR, Hirschman SZ: Cephapirin: pharmacology in normal human volunteers. J Clin Pharmacol 12:81, 1972
Bergan T, Orjavik D, Brodwall EK: Pharmacokinetics of cefapirin in patients with normal and impaired renal function. Arzneimittelforschung (Drug Res) 31:1773, 1981
Bran JL, Levinson ME, Kaye D: Clinical and in vitro evaluation of cephapirin, a new cephalosporin antibiotic. Antimicrob Agents Chemother 1:35, 1972
Cabana BE, Van Harben DR, Hottendorf GH et al.: The role of the kidney in the elimination of cephapirin in man. J Pharmacokinet Biopharm 3:419, 1975
McCloskey RV, Terry EE, McCracken AW, Sweeney MJ, Forland MF: Effect of hemodialysis and renal failure on serum and urine concentrations of cephapirin sodium. Antimicrob Agents Chemother 1:90, 1972
Main references
Anastassiades EG and Curtis JR: In: Cephradine 12 years on -a routine antibiotic for therapy and prophylaxis. International congress and symposium series No. 85, A Percival and P Woods (eds), London: The Royal Society of Medicine, 1985 p 55
Boeschoten EW, Rietra PJGM, Krediet RT, Visser MJ, Arisz L: CAPD peritonitis: A prospective randomized trial of oral versus intraperitoneal treatment with cephradine. J Antimicrob Chemother 16:789, 1985
Höffler D, Koeppe P: Zur Pharmakokinetik intravenös applizierten Cefradins bei normaler und eingeschränkter Nierenfunktion. Münchn Med Wochenschr 117:1169, 1975
Johnson CA, Welling PG, Zimmerman SW: Pharmacokinetics of oral cephradine in continuous ambulatory peritoneal dialysis patients. Nephron 38:57, 1984
Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:184, cephradine.
Minn FL, Sugerman AA, Bernfeld CE: Cephradine excretion in humans with pH-altered urine. J Clin Pharmacol 16:171, 1976
Raman GV: In: Cephradine 12 years on — a routine antibiotic for therapy and prophylaxis, International congress and symposium series No. 85, A Percival and P Woods (eds), London: The Royal Society of Medicine, 1985 p 47
Searle M, Raman GV: Oral treatment of peritonitis complicating continuous ambulatory peritoneal dialysis. Clin Nephrol 23:241, 1985
Solomon AE, Buggs JD, McGleachy R, et al.: The administration of cephradine to patients in renal failure. Br J Clin Pharmacol 2:443, 1975
Main references
De Caro G, Improta G: Disappearance of Caerulein from circulating blood and its inactivation in vitro by tissue homogenates and blood of dogs and rats. Arch Int Pharmacodyn Ther 197:166, 1972
Erspamer V: Caerulein aus Amphibienhaut. Ein Analogon des Säugetiercholezystokinins. Therapiewoche 31:2690, 1981
Go VLW: The physiology of cholecystokinin. In: Bloom SR (ed): Gut hormones, Edinburgh, London, New York: Churchill Livingstone, 1978 p 203
Robberecht P, Cremer M, Vandermeers A, Vandermeers-Piret MC, Cotton P, De Neef P, Christophe J: Pancreatic secretion of total protein and of three hydrolases collected in healthy subjects via duodenoscopic cannulation. Effects of secretin, pancreozymin, and caerulein. Gastroenterology 69:374, 1975
Tokiwa T, Uemura I, Murakami H, Tsuruoka S, Kaneko M, Ogawa K, Manzai T: Studies on Caerulein (Fl 6934). Absorption, distribution, metabolism and excretion of caerulein. Jpn J Pharmacol 25:747, 1975
Main references
Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:1555, chenodeoxycholic acid.
Main references
Berry DJ: Determination of trichloroethanol at therapeutic and overdose levels in blood and urine by electron capture gas chromatography. J Chromatogr 107:107, 1975
Mackay FJ, Cooper JR: A study on the hypnotic activity of chloral hydrate. J Pharmacol Exp Ther 135:271, 1962
Marshall EL jr, Owens AH jr: Absorption, excretion, and metabolic fate of chloral hydrate and trichloroethanol. Bull Johns Hopkins Hosp 95:1, 1954
Sellers EM, Lang ML, Cooper SD, Koch-Weber J: Chloral hydrate and trichlofos metabolism. Clin Pharmacol Ther 14:147, 1973
Seyffart G: Antihistamines and other sedatives. D. Chloral hydrate. In: Haddad LM and Winchester JF (eds): Clinical management of poisoning and drug overdose. Philadelphia: Saunders, 1990, chapter 46, p 835
Stalker NE, Gambertoglio JG, Fukumitsu CJ, Naughton JL, Benet LZ: Acute massive chloral hydrate intoxication treated with hemodialysis: A clinical pharmacokinetic analysis. J Clin Pharmacol 18:136, 1978
Vaziri ND, Kumar KP, Mirahmadi K, Rosen SM: Hemodialysis in treatment of acute chloral hydrate poisoning. South Med J 70:377, 1977
Main references
Adair CG, Bridges JM, Desai ZR: Can food affect the bioavailability of chlorambucil in patients with haematological malignancies? Cancer Chemother Pharmacol 17:99, 1986
Alberts DS, Chang SY, Chen HS, Larcom BJ, Jones SE: Pharmacokinetics and metabolism of chlorambucil in man: a preliminary report. Cancer Treat Rev 6 (Suppl):9, 1979
McLean A, Woods RL, Catovsky D, Farmer P: Pharmacokinetics and metabolism of chlorambucil in patients with malignant disease. Cancer Treat Rev 6 (Suppl):33, 1979
Newell DR, Calvert AH, Harrap KR, McElwain TJ: Studies on the pharmacokinetics of chlorambucil and prednimustine in man. Br J Clin Pharmacol 15:253, 1983
Main references
Birrell DJ, Boyle PD, Craswell PW, Hunt FA: An epidemic of chloramine induced anaemia in a haemodialysis unit. Med J Aust 65(ll):288, 1978
Botella J, Traver JA, Sanz-Guajardo D, Torres MT, Sanjuan I, Zabala P: Chloramines, an aggravating factor in the anaemia of patients on regular dialysis treatment. Proc Eur Dial Transplant Assoc 14:192, 1977
Kjellstrand CM, Eaton JW, Yawata Y, Swofford H, Kolpin CF, Beselmeier TJ, von Hartitzsch B, Jacob HS: Hemolysis in dialyzed patients caused by chloramines. Nephron 13:427, 1974
Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:955, chloramine
Main references
Ambrose PJ: Clinical pharmacokinetics of chloramphenicol and chloramphenicol succinate. Clin Pharmacokinet 9:222, 1984
Blouin RA, Erwin WG, Dutro MP, Bustrack JA, Rowse KL: Chloramphenicol hemodialysis clearance. Ther Drug Monit 2:351, 1980
Grafnetterova J, Vodrazka Z, Jandova D, Schück O, Tomasek R, Lachmanova JL: The binding of chloramphenicol to serum proteins in patients with chronic renal insufficiency. Clin Nephrol 6:448, 1976
Koup J, Lau A, Brodsky B, Slaughter R: Chloramphenicol pharmacokinetics in hospitalized patients. Antimicrob Agents Chemother 15:651, 1979
Kunin CM, Glazko AJ, Finland M: Persistence of antibiotics in blood of patients with acute renal failure. II. Chloramphenicol and its metabolic products in the blood of patients with severe renal disease or hepatic cirrhosis. J Clin Invest 38:1498, 1959
Lindber AA, Nilsson LH, Bucht H: Concentration of chloramphenicol in the urine and blood in relation to renal function. Br Med J 2:724, 1966
Prat V, Grafnetterova J, Schück O, et al.: Comparison of renal excretion of chloramphenicol in patients with chronic pyelonephritis and polypeptic kidneys. Int J Clin Pharmacol Biopharm 13:71, 1976
Slaughter RL, Cerra FB, Koup JR: Effect of hemodialysis on total body clearance of chloramphenicol. Am J Hosp Pharm 37:1083, 1980
Suhrland LF, Weisberger AS: Chloramphenicol toxicity in liver and renal disease. Arch Intern Med 112:747, 1963
Main references
Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:477, chlorcyclizine dibunate.
Main references
Breimer DD, Jochemsen R, Albert HH: Pharmacokinetics of benzodiazepines. Short-acting versus long-acting. Arzneimittelforschung (Drug Res) 30(l):875, 1980
Curry SH, Whelpton R: Pharmacokinetics of closely related benzodiazepines. Br J Clin Pharmacol 8:15S, 1979
Greenblatt DJ, Shader Rl, MacLeod SM, Sellers EM: Clinical pharmacokinetics of chlordiazepoxide. Clin Pharmacokinet 3:381, 1978
Greenblatt DJ, Shader RI, Divoll M, Harmatz JS: Benzodiazepines. A summary of pharmacokinetic properties. Br J Clin Pharmacol 11:11S, 1981
Main references Sclerosing peritonitis
Buckle RG, Seabridge CE: The effect of Chlorhexidine in peritoneal cavity. Lancet 1963,I:193
Fabbri L, Grimaldi C, Zuchelli P: Peritonitis in CAPD: Treatment with Chlorhexidine. Dial & Transplant 11:483, 1982
Junor BJR, Briggs JD, Forwell MA, Dobbie JW, Henderson J: Sclerosing peritonitis. The contribution of Chlorhexidine in alcohol. Perit Dial Bull 5:101, 1985
Mackow RC, Winchester JF, Argy WP, Andrews PM, Fields PA, Bates S, Rakowski TA, Schreiner GE: Sclerosing encapsulating peritonitis in rats: An experimental study with intraperitoneal antiseptics. Contrib Nephrol 57:213, 1987
Rottembourg J, Gahl GM, Poignet JL, Mertani E. Strippoli P, Langlois P, Tranbaloc P, Legrain M: Severe abdominal complications in patients undergoing continuous ambulatory peritoneal dialysis. Proc Eur Dial Transplant Ass 20:236, 1983
Shaldon S, Koch KM, Quellhorst E, Dinarello CA: Pathogenesis of sclerosing peritonitis in CAPD. Trans Am Soc Artif Intern Organs 30:193, 1984
Slingeneyer A, Canaud B, Mourad G, Beraud JJ, Balmes M, Faller B, Mion C: Progressive sclerosing peritonitis: a late and severe complication of maintenance peritoneal dialysis. Trans Am Soc Artif Intern Organs 29:633, 1983
Sobel JD, Hashman N, Reinherz G, Merzbach D: Nosocomial Pseudomonas cepacia infection associated with Chlorhexidine contamination. Am J Med 73:183, 1982
Sommerville PJ, Kaye M: Chlorhexidine is unsuitable for long-term use in patients on CAPD. Perit Dial Bull 4:195, 1982
Suessmuth R, Ackermann B, Lingers F: Mutagenic effect of 1.1′-hexamethylene-bis[(5-p-chlorophenyl)-biguanide]. Chem Biol Interact 28:249, 1979
Main reference
Durwekar YG, Narula RK, Laumas KR: Distribution of α-3H-chlormadinone acetate in the reproductive tract of women. Contraception 7:313, 1973
Main references
Ali SL, Blume H: Determination of chlormezanone in human plasma after administration of chlormezanone formulations. Arzneimittelforschung (Drug Res) 37(II): 1396, 1987
McChesney EW, Banks WF jr, Portmann GA, Crain AVR: Metabolism of chlormezanone in man and laboratory animals. Biochem Pharmacol 16:813, 1967
Main references
Akintonwa A, Odutola TA, Edeki T, Biola Mabadeje AF: Hemodialysis clearance of chloroquine in uremic patients. Ther Drug Monit 8:285, 1986
Barrett-Connor E: Drugs for the treatment of parasitic infection. Med Clin North Am 66:245, 1982
Fabre J, DeFreudenrich J, Duchert A, Pitton JS, Rudhardt M, Virieux C: Influence of renal insufficiency on the excretion of chloroquine, phenobarbital, phenothiazines and methacycline. Helv Medice Acta 303:307, 1967
Frisk-Holmberg M, Bergkvist Y, Domeij-Nyberg B, Hellstrom L, Jansson F: Chloroquine serum concentration and side effects: Evidence for dose-dependent kinetics. Clin Pharmacol Ther 25:345, 1979
Mackenzie AH, Scherbel AL: Chloroquine and hydroxychloroquine in rheumatological therapy. Clin Rheum Dis 6:545, 1980
Mackenzie AH: Pharmacologie actions of 4-aminoquinoline compounds. Am J Med 75 (Suppl. 1A, July):5, 1983
Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:508, chloroquine.
McChesney EW, Conway WD, Banks WF Jr. Rogers JE, Shek-osky JM: Studies of the metabolism of some compounds of the 4-amino-7-chloroquine series. J Pharmacol Exp Ther 15:482, 1966
McChesney EW, Shekosky JM, Hernandez PH: Metabolism of chloroquine-3-14C in the rhesus monkey. Biochem Pharmacol 16:2444, 1967
Ritschel W, Hammer G, Thompson G: Pharmacokinetics of antimalarials and proposals for drug regimens. Int J Clin Pharmacol 16:395, 1978
VanStone JC: Hemodialysis and chloroquine poisoning. J Lab Clin Med 88:87, 1976
Zvaifler NJ, Rubin M, Berstein H: Chloroquine metabolism — drug excretion and tissue deposition. Arthritis Rheum 6:799, 1963
Main references
Bricker NS: Sodium homeostasis in chronic renal disease. Kidney Int 21:868, 1982
Dreifus LS, Duarte CG, Kodama R, Moyer HJ: The effect of thiazide diuretics on the abnormal kidney. Ann Intern Med 53:1170, 1960
Gerber JG: Antihypertensive agents and diuretics. In: Anderson RJ, Schrier RW (eds), Clinical use of drugs in patients with kidney and liver disease, London: Saunders, 1981 p 211
Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:981, chlorothiazide
Main reference
Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:959, chloroxylenol.
Main reference
Forist AA, Judy RW: Comparative pharmacokinetics of chlorphenesin carbamate and methocarbamol in man. J Pharm Sci 60:1686, 1971
Main references
Chiou WL, Athanikar NA, Huang SM: Long half-life of chlorpheniramine. N Engl J Med 300:501, 1979
Lai CM, Stoll RG, Look ZM; Yacobi A: Urinary excretion of chlorpheniramine and pseudoephedrine in humans. J Pharm Sci 68:1243, 1979
Patel JA, Phillips GL: A guide to physical combatibility of intravenous drug admixtures. Am J Hosp Pharm 23:409, 1966
Peets EA, Jackson M, Symchowicz S: Metabolism of chlorpheniramine maleate in man. J Pharmacol Exp Ther 180:464, 1972
Main reference
Goenechea S, Rücker G, Brzezinka H, Hoffmann G, Neugebauer M, Pyzik T: Isolierung von Chlorphenoxamin-Metaboliten aus menschlischem Harn und ihre Identifizierung. Arzneimittelforschung (Drug Res) 37(II):854, 1987
Main references
Dahl SG, Strandjord RE: Pharmacokinetics of chlorpromazine after single and chronic dosage. Clin Pharmacol Ther 21:437, 1977
Loo JC, Midha KK, McGilveray IJ: Pharmacokinetics of chlorpromazine in normal volunteers. Commun Psychopharmacol 4:121, 1980
Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:722, chlorpromazine.
Main references
Arrigoni L, Fundak G, Horn J, Kradjan W, Ellsworth A, Opheim K, Taylor T, Bauer LA: Chlorpropamide pharmacokinetics in young healthy adults and older diabetic patients. Clin Pharm 6:162, 1987
Graw RG, Clarke RR: Chlorpropamide intoxication — treatment with peritoneal dialysis. Pediatrics 45:106, 1970
Petitpierre B, Perrin L, Rudhardt M, Herrera A, Fabre J: Behaviour of chlorpropamide in renal insufficiency and under the effect of associated drug therapy. Int J Clin Pharmacol 6:120, 1972
Sharpstone P: Diseases of the urinary system. Prescribing for patients with renal failure. Br Med J 1977, 2:36
Taylor JA: Pharmacokinetics and biotransformation of chlorpropamide in man. Clin Pharmacol Ther 13:710, 1972
Main references
Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:725, chlorprothixene.
McAllister CJ, Scowden EB, Stone WJ: Toxic psychosis induced by phenothiazine administration in patients with chronic renal failure. Clin Nephrol 10:191, 1978
Raaflaub J: Zum Metabolismus des Chlorprothixen. Arzneimittelforschung (Drug Res) 17:1393, 1967
Raaflaub J: On the pharmacokinetics of chlorprothixene in man. Experientia 31:557, 1975
Main references
Dieterle W, Wagner J, Faigle JW: Binding of chlorthalidone (Hygroton) to blood components in man. Eur J Clin Pharmacol 10:37. 1976
Fleuren HLJM, van Rossum JM: Pharmacokinetics of chlorthalidone in man. Pharm Weekbl (Sci) 110:1262, 1975
Fleuren HLJM, Thein TA, Verwey-van Wissen CPW, van Rossum JM: Absolute bioavailability of chlorthalidone in man. A crossover study after intravenous and oral administration. Eur J Clin Pharmacol 15:35, 1979
Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:983, chlorthalidone.
Mulley BA, Parr GD, Rye RM: Pharmacokinetics of chlorthalidone. Dependence of biological half-life on blood carbonic anhydrase levels. Eur J Clin Pharmacol 17:203, 1980
Tweeddale MG, Ogilvie RI: Absorption and excretion of chlorthalidone (Hygroton) in man. Clin Res 20:913, 1972
Main reference
Stewart JT, Chan CW: Fluorometric determination of chlorzoxazone in tablets and biological fluids J Pharm Sci 68:910, 1979
Main references
Goodman and Gilman’s The pharmacological basis of therapeutics. 7th ed. New York: Macmillan, 1985: 1517, chapter 65, Agents affecting calcification: Calcium, parathyroid hormone, calcitonin, vitamin D, and other compounds by RC Haynes jr and F Murad
Henning HV, Fuchs C: Renale Osteopathie. Nieren- und Hochdruckkrankh 13:235, 1984
Kawashima H, Kurokawa K: Metabolism and sites of action of vitamin D in the kidney. Kidney Int 29:98, 1986
Main references
Martindale. The extra pharmacopoeia. 29th. ed. London: The Pharmaceutical Press, 1989:1197, cholestyramine.
Silverberg DS, laina A, Reisin E, Rotzak R, Eliahou HE: Cholestyramine in uraemic pruritus. Br Med J 1977, 1:752
Main reference
Goodman and Gilman’s The pharmacological basis of therapeutics. 7th ed. New York: Macmillan, 1985:1551, chapter 66, Water-soluble vitamins by R Marcus and AM Coulston
Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:1258, choline
Main references General
Cohen A, Thomas GB, Cohen EB: Serum concentration, safety and tolerance of oral doses of choline magnesium trisalicy-late. Curr Ther Res 23:358, 1978
Main references Renal damage
Abraham PA, Keane WF: Glomerular and interstitial disease induced by nonsteroidal anti-inflammatory drugs. Am J Nephrol 4:1, 1984
Carmichael J, Shankel SW: Effects of non-steroidal anti-inflammatory drugs on prostaglandins and renal function. Am J Med 78:992, 1985
Clive DM, Stoff JS: Renal syndromes associated with nonsteroidal anti-inflammatory drugs. N Engl J Med 310:563, 1984
Duggin GG: Mechanisms in the development of analgesic nephropathy. Kidney Int 18:553, 1980
Dunn MJ: Non-steroidal anti-inflammatory drugs and renal function. Annu Rev Med 35:411, 1984
Hart D, Lifschitz MD: Renal physiology of the prostaglandins and the effects of nonsteroidal anti-inflammatory agents on the kidney. Am J Nephrol 7:408, 1987
Henrich WL: Nephrotoxicity of nonsteroidal anti-inflammatory agents. Am J Kidney Dis 2:478, 1982
Orme ML’E: Non-steroidal anti-inflammatory drugs and the kidney. Br Med J 292:1521, 1986
Reeves WB, Foley RJ, Weinman EJ: Renal dysfunction from nonsteroidal anti-inflammatory drugs. Arch Intern Med 144:1943, 1984
Simon LS, Mills JA: Nonsteroidal antiinflammatory drugs (First of two parts). N Engl J Med 302:1179, 1980
Simon LS, Mills JA: Nonsteroidal antiinflammatory drugs (Second of two parts). N Engl J Med 302:1237, 1980
Torres VE: Present and future of non-steroidal anti-inflammatory drugs in nephrology. Mayo Clin Proc 57:389, 1982
Toto RD, Anderson SA, Brown-Cartwright D, Kokko JP, Brater DG: Effects of acute and chronic dosing of NSAIDs in patients with renal insufficiency. Kidney Int 30:760, 1986
Wegmüller E: Nicht-steroidale Antirheumatika und Nephrotoxi-zität. Dtsch Med Wochenschr 110:469, 1985
Main references
Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:1144, chorionic gonadotropin
Ross GT: Clinical relevance of research on the structure of human chorionic gonadotropin. Am J Obstet Gynecol 129:795, 1977
Main reference
Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:193, ciclacillin
Main references
Gibson TP, Demetriades JL, Bland JA: Imipenem/cilastatin: pharmacokinetic profile in renal insufficiency. Am J Med 78 (Suppl 6A): 54, 1985
Rogers JD, Meisinger MAP, Ferber F, Calandra GB, Demetriades JL, Bland JA: Pharmacokinetics of imipenem and cilastatin in volunteers. Rev Infect Dis 7 (Suppl 3):S435, 1985
Verpooten GA, Verbist L, Buntinx AP, Entwistle LA, Jones KH, De Broe ME: The pharmacokinetics of imipenem (thienamy-cin-formamidine) and the renal dehydropeptidase inhibitor cilastatin sodium in normal subjects and patients with renal failure. Br J Clin Pharmacol 18:183, 1984
Main references
Bjaeldager PAL, Jensen JB, Larsen NE, Hvidberg EF: Elimination of oral Cimetidine in chronic renal failure and during haemo-dialysis. Br J Clin Pharmacol 9:585, 1980
Bjaeldager PAL, Jensen JB, Nielsen LP, Larsen NE, Hvidberg EF: Pharmacokinetics of Cimetidine in patients undergoing hemodialysis. Nephron 34:159, 1983
Burland WL, Duncan WAM, Hesselbo T, Mills JG, Sharpe PC, Haggie SJ, Wyllie JH: Pharmacological evaluation of Cimetidine. A new histamine H2-receptor antagonist, in healthy man. Br J Clin Pharmacol 2:481, 1975
Dubb JW, Stote RM, Familiar RG, Lee K, Alexander F: Effect of Cimetidine on renal function in normal man. Clin Pharmacol Ther 24:76, 1978
Finkelstein W, Isselbacher KJ: Cimetidine. N Engl J Med 299: 992, 1978
Hyneck ML, Murphy JF, Lipschutz DE: Cimetidine clearance during intermittent and chronic peritoneal dialysis. Am J Hosp Pharm 38:1760, 1981
Jones RH, Lewin MR, Parsons V: Therapeutic effect of Cimetidine in patients undergoing haemodialysis. Br Med J 1:650, 1979
Kaye WA, Passero MA, Solomon RJ, Johnson LA: Cimetidine-induced interstitial nephritis with response to prednisone therapy. Arch Intern Med 143:811, 1983
Krichman KH, Cutler RE, Blair AD: Pharmacokinetics of Cimetidine in normal and uremic humans. W Soc Clin Pharmacol Ther 27:73A. Abstract
Larsson R, Erlanson P, Bodemar G, Norlander B, Fransson L, Strouth L: Pharmacokinetics of Cimetidine and its sulphoxide metabolite during haemodialysis. Eur J Clin Pharmacol 21:325, 1982
Ma KW, Brown DC, Masler DS, Silvis SE: Effects of renal failure on blood levels of cimetidine. Gastroenterology 74:473, 1978
Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:1082, Cimetidine.
Pedersen PV, Miller R: Pharmacokinetics and bioavailability of cimetidine in humans. J Pharm Sci 69:394, 1980
Pizzella KM, Moore MC, Schultz RW, Walshe J, Schentag JJ: Removal of cimitidine by peritoneal dialysis, hemodialysis, and charcoal hemoperfusion. Ther Drug Monit 2:273, 1980
Randolph WC, Osborne VL, Walkenstein SS. Intoccia AP: High-pressure liquid chromatographic analysis of cimetidine, a histamine H2-.receptor antagonist, in blood and urine. J. Pharm Sci 66:1148, 1977
Sawyer D, Conner CS, Scalley R: Cimetidine: Adverse reactions and acute toxicity. Am J Hosp Pharm 38:188, 1981
Sedman AJ: Cimetidine-drug interactions. Am J Med 76:109, 1984
Somogyi A, Gugler R: Clinical pharmacokinetics of Cimetidine. Clin Pharmacokinet 8:463, 1983
Vaziri ND, Ness R, Barton CH: Hemodialysis clearance of Cimetidine. Arch Intern Med 138:1685, 1978
Vaziri ND, Ness RL, Barton CH: Peritoneal dialysis clearance of Cimetidine. Am J Gastroenterol 71:572, 1979
Main references
Abranyi I: Therapeutische Erfahrungen mit Stugeron. Ther Hung 21:132, 1973
Allewijn FTN: The distribution of cinnarizine and its metabolites in the rat. Life Sci 7 (Part l):989, 1968
Ellis F, Hyams DE, Jageneau AHM, Loots W: Vascular effects of cinnarizine in patients with intermittent claudication. J Int Med Res 3:93, 1975
Soudijn W, van Wijngaarden I: The metabolism and excretion of cinnarizine by rats. Life Sci 7:231, 1968
Trumbull R, Chinn HI, Maag CH, Milch LJ, Handford SW, Seibert R, Sperling P, Smith PK: Effect of certain drugs on the incidence of seasickness. Clin Pharmacol Ther 1:280, 1960
Main references
Brogard JM, Comte F, Lavillaureix J: Comparative pharmacokinetic profiles of cinoxacin and pipemidic acid in humans. Eur J Drug Metab Pharmacokinet 8:251, 1983
Sisca TS, Heel RC, Romankiewics JA: Cinoxacin: A review of its pharmacological properties and therapeutics efficacy in the treatment of urinary tract infections. Drugs 25:544, 1983
Szwed JJ, Brannon DE, Sloan RS, Luft FC: Pharmacokinetics of cinoxacin in patients with renal failure. J Antimicrob Chemother 4:451, 1978
Main references
Aronoff GE, Kenner CH, Sloan RS, Pottratz ST: Multiple-dose ciprofloxacin kinetics in normal subjects. Clin Pharmacol Ther 36:384, 1984
Bergan T, Thorsteinsson SB, Kolstad IM, Johnsen S: Pharmacokinetics of ciprofloxacin after intravenous and increasing oral doses. Eur J Clin Microbiol 5:187, 1986
Bergan T, Dalhoff A, Rohwedder R: Pharmacokinetics of ciprofloxacin. Infection 16, Suppl 1:S3, 1988
Boelaert J, Valcke Y, Schurgers M, Daneels R, Rosseneu M, Rosseel MT, Bogaert MG: The pharmacokinetics of ciprofloxacin in patients with impaired renal function. J Antimicrob Chemother 16:87, 1985
Brogard JM, Jehl F, Monteil H, Adloff M, Blickle JF, Levy P: Comparison of high-pressure liquid chromatography and microbiological assay for the determination of biliary elimination of ciprofloxacin in humans. Antimicrob Agents Chemother 28:311, 1985
Crump B, Wise R, Dent J: Pharmacokinetics and tissue penetration of ciprofloxacin. Antimicrob Agents Chemother 24:784, 1983
Daschner FD, Westenfelder M, Dalhoff A: Penetration of ciprofloxacin into kidney fat, muscle and skin tissue. Eur J Clin Microbiol 5:212, 1986
Dharmasena D, Roberts DE, Coles GA, Williams JD: Pharmacokinetics of intraperitoneal ciprofloxacin in patients on CAPD. J Antimicrob Chemother 23:253, 1989
Golper TA, Hartstein AI, Morthland VH, Christensen JM: Effects of antacids and dialysate dwell times on multiple-dose pharmacokinetics of oral ciprofloxacin in patients on continuous ambulatory peritoneal dialysis. Antimicrob Agents Chemother 31:1787, 1987
Gonzalez MA, Uribe F, Moisen SD, Fuster AP, Selen A, Welling PG, Painter B: Multiple-dose pharmacokinetics and safety of ciprofloxacin in normal volunteers. Antimicrob Agents Chemother 26:741, 1984
Höffken G, Lode H, Prinzing Z, Borner K, Koeppe P: Pharmacokinetics of ciprofloxacin after oral and parenteral administration. Antimicrob Agents Chemother 27:375, 1985
Höffler D, Dalhoff A, Gan W, Beermann D, Michl A: Dose- and sex-independent disposition of ciprofloxacin. Eur J Clin Microbiol 3:363, 1984
Nix DE, De Vito JM: Ciprofloxacin and norfloxacin, two fluoroquinolone antimicrobials. Clin Pharm 6:105, 1987
Roberts DE, Williams JD: Ciprofloxacin in renal failure (leading article). J Antimicrob Chemother 23:820, 1989
Shalit I, Greenwood RB, Marks MI, Pederson JA, Frederick DL: Pharmacokinetics of single-dose oral ciprofloxacin in patients undergoing chronic ambulatory peritoneal dialysis. Antimicrob Agents Chemother 30:152, 1986
Shalit I, Kitzes-Cohen R, Rapoport J, Schlaeffer F, Chaimovitz C: Pharmacokinetics of ciprofloxacin in patients receiving peritoneal dialysis and being treated for peritonitis. Rev Infect Dis 11, Suppl 5:14, 1989
Singlas E, Taburet AM, Landru I, Albin H, Ryckelinck JP: Pharmacokinetics of ciprofloxacin tablets in renal failure; influence of haemodialysis. Eur J Clin Pharmacol 31:589, 1987
Smith JT: Awakening the slumbering potential of the 4-quinolone antibacterials. Pharm J 233:299, 1984
Staib AH, Beermann D, Harder S, Fuhr M, Liermann J: Differences of ciprofloxacin absorption along the gastrointestinal tract in man (Results of an HF-capsule-study). Naunyn Schmiedebergs Arch Pharmacol 338 (Suppl):R81, 1988
Wingender W, Graefe KH, Gau W, Förster D, Beermann D, Schacht P: Pharmacokinetics of ciprofloxacin after oral and intravenous administration in healthy volunteers. Eur J Clin Microbiol 3:355, 1984
Zeiler HJ, Petersen U, Gau W, Ploschke HJ: Antibacterial activity of the metabolites of ciprofloxacin and its significance in the bioassay. Arzneimittelforschung (Drug Res) 37(I):131, 1987
Main references
Bitran JD, Desser RK, Billing AA et al.: Acute nephrotoxicity following cis-dichlorodiammine platinum. Cancer 49:1784, 1982
Blachey JD, Hill JB: Renal and electrolyte disturbances associated with cisplatin. Ann Intern Med 95:628, 1981
DeConti RC, Toftness BR, Lange RC, Creasey WA: Clinical and pharmacological studies with cis-diamminedichloroplatinum II. Cancer Res 33:1310, 1973
Dentino M, Luft FC, Yum MN, Williams SD, Einhorn LH: Long term effect of cis-diamminedichloride platinum (CDDP) on renal function and structure. Cancer 41:1274, 1978
Einhorn LH, Williams SD: The role of cis-platinum in solid tumor therapy. N Engl J Med 300:289, 1979
Gonzalez-Vitale JC, Hayes DM, Cvitkovic E, Sternberg SS: The renal pathology in clinical trials of cis-platinum (II) diamminedichloride. Cancer 39:1362, 1977
Gonzalez-Vitale JC, Hayes DM, Cvitkovic E, Sterberg SS: Acute renal failure after cis-dihlorodiammine platinum (II) and gentamicin-cephalotin therapies. Cancer Treat Rep 62:693, 1978
Gormley PE, Bull JM, LeRoy AF, Cysyk R: Kinetics of cis-dichlorodiammineplatinum. Clin Pharmacol Ther 25:351, 1979
Hayes DM, Cvitkovic E, Golbey RB, Scheiner E, Helson L, Krakoff IH: High-dose cis-platinum diammine dichloride: amelioration of renal toxicity by mannitol diuresis. Cancer 39:1372, 1977
Madias NE, Harrington JT: Platinum nephrotoxicity. Am J Med 65:307, 1978
Prestayko AW, Luft FC, Einhorn L, Crooke ST: Cis-platinum pharmacokinetics in a patient with renal dysfunction. Med Pediatr Oncol 5:183, 1978
Schilsky RL, Howell SB: Hypomagnesemia and renal magnesium wasting in patients receiving cisplatin. Ann Intern Med 90:929, 1979
Stark JJ, Howell SB: Nephrotoxicity of cis-platinum (II) dichlorodiammine. Clin Pharmacol Ther 23:461, 1978
Ward JM, Grabin ME, Berlin E, Young DM: Prevention of renal failure in rats receiving cis-diammine dichloroplatinum (II) by administration of furosemide. Cancer Res 37:1238, 1977
Main references
Bodey GP, Yeo E, Ho DH, Rolston K, LeBlanc B: Clinical pharmacology of timentin (ticarcillin and clavulanic acid). Clin Pharmacol Ther 37:134, 1985
Horber FF, Frey FJ, Descoeudres C, Murray AT, Reubi FC: Differential effect of impaired renal function on the kinetics of clavulanic acid and amoxicillin. Antimicrob Agents Chemother 29:614, 1986
Jackson D, Cooper DL, Filer CW, Langley PF: Augmentin, absorption, excretion and pharmacokinetic studies in man. Postgrad Med 76 (Suppl):51, 1984
Koeppe P, Höffler D, Hulla FW: Pharmacokinetic studies on clavulanate potentiated ticarcillin in normal subjects and patients with renal insufficiency. Arzneimittelforschung (Drug Res) 37:203, 1987
Slaughter RL, Kohli R, Brass C: Effects of hemodialysis on the pharmacokinetics of amoxicillin/clavulanic acid combination. Ther Drug Monit 6:424, 1984
Main references
Sandoz (Basel, Switzerland): Dokumentation Tavegil (1984)
Tham R, Norlander B, Hägermark Ö, Fransson L: Gaschromatography of clemastine. A study of plasma kinetics and biological effect. Arzneimittelforschung (Drug Res) 280(I):1017, 1978
Main references
Offerhaus L: Clenbuterol: het ‘herverdelingsmiddel’. Ned Tijdschr Geneeskd 132:1782, 1988
Yamamoto I, Iwata K, Nakashima M: Pharmacokinetics of plasma and urine clenbuterol in man, rat and rabbit. J Pharmacobiodyn 8:385, 1985
Zimmer A: Einmalapplikation, Mehrfachapplikation und Metabolitenmuster von Clenbuterol beim Menschen. Arzneimittelforschung (Drug Res) 26:1446, 1976
Main references
Brandl R, Arkenau C, Simon C, Malerczyk V, Eidelloth G: Zur Pharmakokinetik von Clindamycin bei gestörter Leber- und Nierenfunktion. Dtsch Med Wochenschr 97:1057, 1972
Cimino JE, Tierno PM jr: Hemodialysis of clindamycin (7-chloro-7-deoxylincomycin). Appl Microbiol 17:446, 1969
DeHaan RM, Metzler CM, Schellenberg D, et al.: Pharmacokinetic studies of clindamycin hydrochloride in humans. Int J Clin Pharmacol 6:105, 1972
Eastwood JB, Gower PE: A study of the pharmacokinetics of clindamycin in normal subjects and patients with chronic renal failure. Postgrad Med J 50:719, 1974
Fass RJ, Saslaw S: Clindamycin: Clinical and laboratory evaluation of parenteral therapy. Am J Med Sci 263:369, 1972
Golper TA, Sewell DL, Fisher PB, Wolfson M: Incomplete activation of intraperitoneal clindamycin phosphate during peritoneal dialysis. Am J Nephrol 4:38, 1984
Roberts AP, Eastwood JB, Gower PE, Fenton CM, Curtis JR: Serum and plasma concentrations of clindamycin following a single intramuscular injection of clindamycin phosphate in maintenance haemodialysis patients and normal subjects. Eur J Clin Pharmacol 14:435, 1978
Main references
Berggren L, Hansson O: Absorption of intestinal antiseptics derived from 8-hydroxyquinolines. Clin Pharmacol Ther 9:67, 1968
Jack DB, Riess W: Pharmacokinetics of iodochlorhydroxyquin in man. J Pharm Sci 62:1929, 1973
Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press. 1989:661. clioquinol.
Main references
Brogden RN, Heel RC, Speight TM, Avery GS: Clobazam: A review of its pharmacological properties and therapeutic use in anxiety. Drugs 20:161, 1980
Greenblatt DJ, Divoll M, Abernethy DR, Ochs HR, Shader RI: Clinical pharmacokinetics of the newer benzodiazepines. Clin Pharmacokinet 8:233, 1983
Main references General
Thuillier J, Bessin P, Geffroy F, Godfroid JJ: Chimie et pharmacoligie de la Clofezone. Bull Chimie Therapeutique 1968, No 1:53
Main references Renal damage
Abraham PA, Keane WF: Glomerular and interstitial disease induced by nonsteroidal anti-inflammatory drugs. Am J Nephrol 4:1, 1984
Carmichael J, Shankel SW: Effects of non-steroidal anti-inflammatory drugs on prostaglandins and renal function. Am J Med 78:992, 1985
Clive DM, Stoff JS: Renal syndromes associated with nonsteroidal anti-inflammatory drugs. N Engl J Med 310:563, 1984
Duggin GG: Mechanisms in the development of analgesic nephropathy. Kidney Int 18:553, 1980
Dunn MJ: Non-steroidal anti-inflammatory drugs and renal function. Annu Rev Med 35:411, 1984
Hart D, Lifschitz MD: Renal physiology of the prostaglandins and the effects of nonsteroidal anti-inflammatory agents on the kidney. Am J Nephrol 7:408, 1987
Henrich WL: Nephrotoxicity of nonsteroidal anti-inflammatory agents. Am J Kidney Dis 2:478, 1982
Orme ML’E: Non-steroidal anti-inflammatory drugs and the kidney. Br Med J 292:1521, 1986
Reeves WB, Foley RJ, Weinman EJ: Renal dysfunction from nonsteroidal anti-inflammatory drugs. Arch Intern Med 144:1943, 1984
Simon LS, Mills JA: Nonsteroidal antiinflammatory drugs (First of two parts). N Engl J Med 302:1179, 1980
Simon LS, Mills JA: Nonsteroidal antiinflammatory drugs (Second of two parts). N Engl J Med 302:1237, 1980
Torres VE: Present and future of non-steroidal anti-inflammatory drugs in nephrology. Mayo Clin Proc 57:389, 1982
Toto RD, Anderson SA, Brown-Cartwright D, Kokko JP, Brater DG: Effects of acute and chronic dosing of NSAIDs in patients with renal insufficiency. Kidney Int 30:760, 1986
Wegmüller E: Nicht-steroidale Antirheumatika und Nephrotoxizität. Dtsch Med Wochenschr 110:469, 1985
Main references
Bridgman JF, Rosen SM, Thorp JM: Complications during clofibrate treatment of nephrotic-syndrome hyperlipoproteinaemia. Lancet II:506, 1972
DiGiulio S, Boulu R, Drueke T et al.: Clofibrate treatment of hyperlipidemia in chronic renal failure. Clin Nephrol 8:504, 1977
Faed EM, McQueen EG: Plasma half-life of clofibric acid in renal failure. Br J Clin Pharmacol 7:407, 1979
Gokal R, Mann JI, Oliver DO, Ledingham JGG, Carter RD: Treatment of hyperlipidaemia in patients on chronic haemodialysis. Br Med J 1:82, 1978
Goldberg AP, Sherrard DJ, Haas LB, Brunzell JD: Control of clofibrate toxicity in uremic hypertriglyceridemia. Clin Pharmacol Ther 21:317, 1977
Gugler R: Clinical pharmacokinetics of hypolipidaemic drugs. Clin Pharmacokinet 3:425, 1978
Harvengt C, Desager JP: Plasma clofibric acid (CPIB) levels induced by three marketed compounds releasing clofibric acid, in volunteers. Int J Clin Pharmacol Biopharm 15:1, 1977
Merk W, Graben N, Hartmann H, Nikolaus C, Schliert G, Schwandt P: Serum levels of free non-protein bound clofibrinic acid after single dosing to patients with impaired renal function of various degrees — a multicenter study. Int J Clin Pharmacol Ther Toxicol 25:59, 1987
Moses AM, Howanitz J, Van Gemert M et al.: Clofibrate-induced antidiuresis. J Clin Invest 52:535, 1977
Pierides AM, Alvarez-Ude F, Kerr DNS: Clofibrate-induced muscle damage in patients with chronic renal failure. Lancet II:1279, 1975.
Sherrard DJ, Goldberg AD, Haas LB, Brunzell JD: Chronic clofibrate therapy in maintenance hemodialysis patients. Nephron 25:219, 1980
Viikari J, Anttila M, Kasanen A: The use of clofibrate in patients with renal insufficiency. Int J Clin Pharmacol Ther Toxicol 21:77, 1983
Main references
Harvengt C, Desager JP: Pharmacokinetic study and bioavailability of three marketed compounds releasing p-chlorphenoxyisobutyric acid (CPIB) in volunteers. Int J Clin Pharmacol Biopharm 14:113, 1976
Harvengt C, Desager JP: Plasma clofibric acid (CPIB) levels induced by three marketed compounds releasing clofibric acid, in volunteers. Int J Clin Pharmacol Biopharm 15:1, 1977
Main references
Ende M, Spiteller G, Remberg G, Heipertz R: Urinary metabolites of clomethiazole. Detection and structural analysis by gas chromatography-mass spectrometry. Arzneimittelforsch (Drug Res) 29(II):1655, 1979
Fischler M, Frisch EP, Ortengren P: Plasma concentrations after oral administration of different pharmaceutical preparations of clomethiazole. Acta Pharm Suec 10:483, 1973
Moore RG, Triggs EJ, Shanks CA, Thomas J: Pharmacokinetics of chlormethiazole in humans. Eur J Clin Pharmacol 8:353, 1975
Main references
Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:1394, clomiphene citrate.
Main references
Faigle JW, Dieterle W: The metabolism and pharmacokinetics of clomipramine (Anafranil). J Int Med Res 1:281, 1973
Jones RB, Tech B, Luscombe DK: Plasma levels studies with clomipramine (Anafranil). J Int Med Res 5 (Suppl 1):98, 1977
Luscombe DK: Pharmacokinetics of clomipramine. Br J Clin Pract 33 (Suppl 3):35, 1979
Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:358, clomipramine hydrochloride.
Potter WZ, Calil HM, Manian AA, Zavadil AP, Goodwin FK: Hydroxylated metabolites of tricyclic antidepressants: Preclinical assessment of activity. Biol Psychiatry 14:601, 1979
Main references
Klotz U, Kangas L, Kants J: Clinical pharmacokinetics of benzodiazepines. Prog in pharmacol vol. 3, Stuttgart: G. Fischer Verlag, 1980
Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:402, clonazepam.
Main references
Frisk-Holmberg M, Paalzow L, Edlund PO: Clonidine kinetics in man — evidence for dose dependency and changed pharmacokinetics during chronic therapy. Br J Clin Pharmacol 12:653, 1981
Houston MC: Clonidine hydrochloride: Review of pharmacologic and clinical aspects. Prog Cardiovasc Dis 23:337, 1981
Hulter HN, Licht JH, Ilnicki LP, Singh S: Clinical efficacy and pharmacokinetics of clonidine in hemodialysis and renal insufficiency. J Lab Clin Med 94:223, 1979
Lowenstein J: Drugs five years later: Clonidine. Ann Intern Med 92:74, 1980
Lowenthal DT, Affrime MB, Meyer A, Kim KE, Falkner B, Sharif K: Pharmacokinetics and pharmacodynamics of clonidine in varying states of renal function. Chest 83 (Febr. Suppl 2):386, 1983
Mirkin BL, Green TP, O’Dea RF: Disposition and pharmacodynamics of diuretics and antihypertensive agents in renal disease. Eur J Clin Pharmacol 18:109, 1980
Main references
Bricker NS: Sodium homeostasis in chronic renal disease. Kidney Int 21:868, 1982
Dreifus LS, Duarte CG, Kodama R, Moyer HJ: The effect of thiazide diuretics on the abnormal kidney. Ann Intern Med 53:1170, 1960
Gerber JG: Antihypertensive agents and diuretics. In: Anderson RJ, Schrier RW (eds). Clinical use of drugs in patients with kidney and liver disease, London: Saunders, 1981 p 211
Main references
Ochs HR, Steinhaus E, Locniskar A, Knüchel M, Greenblatt DJ: Desmethyldiazepam kinetics after intravenous, intramuscular, and oral administration of clorazepate dipotassium. Klin Wochenschr 60:411, 1982
Ochs HR, Rauh HW, Greenblatt DJ, Kaschell HJ: Clorazepate dipotassium and diazepam in renal insufficiency: Serum concentrations and protein binding of diazepam and desmethyldiazepam. Nephron 37:100. 1984
Main references
Ochs HR, Greenblatt DJ, Verburg-Ochs B, Harmatz JS, Grehl H: Disposition of clotiazepam: Influence of age, sex, oral contraceptives, cimetidine, isoniazid and ethanol. Eur J Clin Pharmacol 26:55, 1984
Main references
Duhm B, Maul W, Medenwald H, Patzschke H, Pütter J, Wegner LA: The pharmacokinetics of clotrimazole 14C. Postgrad Med J 50 (Suppl 1): 13, 1974
Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:421, clotrimazole.
Menz HP, Teltscher U, Bayer C, v Oldershausen HF: Zur Pharmakokinetik des oralen Antimykotikums Clotrimazol beim Menschen. Dtsch Med Wochenschr 98:1606, 1973
Owens NJ, Nightingale CH, Schweizer RT, Schauer PK, Dekker PT, Quintiliani R: Prophylaxis of oral candidiasis with clotrimazole troches. Arch Intern Med 144:290, 1984
Plempel M, Bartmann K, Büchel H, Regel E: Experimentelle Befunde über ein neues, oral wirksames Antimykotikum mit breitem Wirkungsspektrum. Dtsch Med Wochenschr 94:1356, 1969
Rozenkranz H, Pütter J: The binding of clotrimazole to the proteins of human serum. Eur J Drug Metab Pharmacokinet 1:73, 1976
Weuta H: Klinische Erfahrungen mit der systemischen Verabreichung von Clotrimazol: Pharmakokinetik, Wirkung, Verträglichkeit. Arzneimittelforschung (Drug Res) 24:540, 1974
Main reference
Nauta EH, Mattic H: Pharmacokinetics of flucloxacillin and doxacillin in healthy subjects and patients on chronic intermittent hemodialysis. Br J Clin Pharmacol 2:111, 1975
Main references
Court-Brown CM: The effect of external skeletal fixation on bone healing and bone blood supply. Clin Orthop 201:278, 1985
Ford K, Harris CC, Coleman RE, Dunnick NR: The radionuclide renogram as a predictor of relative renal blood flow. Radiology 149:819, 1983
Selman J (ed): Fundamentals of X-ray and radium physics, (6th ed.) Springfield, II.: Charles Thomas, 1977 p 495
Selman J (ed): Fundamentals of X-ray and radium physics, (6th ed.) Springfield, II.: Charles Thomas, 1977 p 505
Main references
Caldwell J, Sever PS: The biochemical pharmacology of abused drugs. I. Amphetamines, cocaine and LSD. Clin Pharmacol Ther 16:625, 1974
Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:1213, cocaine.
Tucker GT, Mather LE: Properties, absorption, and disposition of local anesthetic agents. In: Cousins MJ (ed): Neural blockade in clinical anesthesia and management of pain, 2nd ed., Philadelphia: JB Lippincott, 1988 p 47
Main references
Bechtel WD, Sinterhauf K: Plasma level and renal excretion of (3H) codeine phosphate in man and in the dog. Arzneimittelforschung (Drug Res) 28(I):308, 1978
Duquette PH, Peterson FJ, Crankshaw DL, Lindemann NJ, Holtzman JL: Studies on the metabolic N- and O-demethylation of (6-3H)codeine. Drug Metab Dispos 11:477, 1983
Guay DRP, Matzke GR, Findlay JWA, Halstenson CE, Awni WM, Opsahl JA, Abraham PA: Codeine pharmacokinetics (PK) and pharmacodynamics (PD) in hemodialysis (HD) patients. Clin Pharmacol Ther 41:222, 1987
Levine DF: Hypocalcaemia increases the narcotic effect of codeine. Postgrad Med J 56:736, 1980
Matzke GR, Chan GLC, Abraham PA: Codeine dosage in renal failure. Clin Pharm 5:15, 1986
Ritschel WA: Pharmacokinetic aspects of analgesics. Methods Find Exp Clin Pharmacol 4:479, 1982
Vaughan DP, Beckett AH: The influence of reducing the C7-C8 double bond of codeine to give dihydrocodeine on the relative physiological availability of the drugs in man. J Pharm Pharmacol 25 (Suppl.): 104P, 1973
Way EL, Adler TK: The biological disposition of morphine and its surrogates. 2. Bull WHO 26:51, 1962
Main references
Carr AA: Colchicine toxicity. Arch Intern Med 115:29, 1965
Cheigh JS: Drug administration in renal failure. Am J Med 62:555, 1977
Donigian DW, Owellen RJ: Interaction of vinblastine, vincristine and colchicine with serum proteins. Biochem Pharmacol 22:2113, 1973
Ellwood MG, Robb GH: Self-poisoning with colchicine. Postgrad Med J 47:129, 1971
Goodman and Gilman’s The pharmacological basis of therapeutics. 7th ed. New York: Macmillan, 1985:674, chapter 29, Analgesic-antipyretics and anti-inflammatory agents; drugs employed in the treatment of gout by RJ Flower, D Moncada and JR Vane
Knepshield JH, Schreiner GE, Lowenthal DT, Gelfand MC: Dialysis of poisons and drugs — annual review. Trans Am Soc Artif Intern Organs 19:590, 1973
Kuncl RW, Duncan G, Watson D, Alderson K, Rogawski MA, Peper M: Colchicine myopathy and neuropathy. N Engl J Med 316:1562, 1987
Wallace SI, Omokoku B, Ertel NH: Colchicine plasma levels. Implications as to pharmacology and mechanism of action. Am J Med 48:443, 1970
Main reference
Düntsch G: Colestipol bei Hypercholesterinämie bei Diabetikern. Fortschr Med 95:1492, 1977
Main references
Adler S, Segel DP: Nonoliguric renal failure secondary to sodium colistimethate: A report of four cases. Am J Med Sci 262:109, 1971
Brown JM, Dorman DC, Roy LP: Acute renal failure due to overdosage of Colistin. Med J Aust 2:923, 1970
Curtis JR, Eastwood JB: Colistin sulphomethate sodium administration in the presence of severe renal failure and during haemodialysis and oeritoneal dialysis. Br Med J 1:484, 1968
Froman J, Gross L, Curatola S: Serum and urine levels following parenteral administration of sodium colistimethate to normal individuals. J Urol 103:210, 1970
Gibaldi M, Perrier D: Drug distribution and renal failure. J Clin Pharmacol 12:201, 1972
Goodman and Gilman’s The pharmacological basis of therapeutics. 7th ed. New York: Macmillan, 1985:1170, chapter 52, Antimicrobial agents by MA Sande and GL Mandell
Goodwin NJ, Friedman EA: The effect of renal impairment, peritoneal dialysis, and hemodialysis on serum sodium colistimethate levels. Ann Intern Med 68:984, 1968
Koch-Weser J, Sidel VW, Federman EB, Kanarek P, Finer DC, Eaton AE: Adverse effects of sodium colistimethate: manifestations and specific reaction rates during 317 courses of therapy. Ann Intern Med 72:857, 1970
Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:204, Colistin sulphate
Price DJE, Graham Dl: Effects of large doses of colistin sulphomethate sodium on renal function. Br Med J 4:525, 1970
Sharpstone P: Diseases of the urinary system. Prescribing for patients with renal failure. Br Med J 2:36, 1977
Swick HM, Maxwell E, Charache P, Levin S: Peritoneal dialysis in colistin intoxication: Report of a case. J Pediatr 74:976, 1969
Vinnicombe J, Stamey TA: The relative nephrotoxicities of polymyxin B sulfate, sodium sulfomethyl-polymyxin B, sodium sulfomethyl-colistin (Colymycin), and neomycin sulfate. Invest Urol 6:505, 1969
Wolinsky E, Hines JD: Neurotoxic and nephrotoxic effects of Colistin in patients with renal disease. N Engl J Med 266:759, 1962
Main reference
Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:1139, corticotrophin
Main references
Asbach HW, Vecsei P, Schüler HW, Gless KH: Serum- und Dialysatspiegel von Corticosteroiden bei Langzeit-Hämodialyse. Dtsch Med Wochenschr 98:1758, 1973
Bacon GF, Kenny FM, Murdaugh HV, Richards C: Prolonged serum half-life of Cortisol in renal failure. Johns Hopkins Med J 132:127, 1973
Deck KA: Das Verhalten der 11-Hydroxycorticoide im Plasma während der extracorporalen Hämodialyse. Klin Wochenschr 45:1006, 1967
Knapp E, Staudinger E, Dittrich P: Das Verhalten des freien Plasmacortisols während extracorporaler Hämodialyse. Klin Wochenschr 48:1243, 1970
Peterson RE, Pierce CE, Wyngaarden JB, Bunim JJ, Brodie BB: The physiological disposition and metabolic fate of cortisone in man. J Clin Invest 36:1301, 1957
Main references
Andreasen F, Elsborg L, Husted S, Thomsen O: Pharmacokinetics of sulfadiazine and trimethoprim in man. Eur J Clin Pharmacol 14:57, 1978
Appel GB, Neu HC: The nephrotoxicity of antimicrobial agents (First of three parts). N Engl J Med 296:663, 1977
Goldsmith HJ, Makamoto S, Kolff WJ: Expanding the indications for treatment with the artificial kidney. Burns, cerebral oedema, sulphonamide intoxication, and congestive heartfailure. Lancet 11:111, 1960
Leone N, Barzaghi N, Monteleone M, Perucca E, Cerutti R, Crema A: Pharmacokinetics of co-trimazine after single and multiple doses. Arzneimittelforschung (Drug Res) 37(I): 70, 1987
Main references
Bourgault AM, Van Scoy RE, Brewer NS, Rosenow EC: Trimethoprim with sulfamethoxazole for treatment of infection with Pneumocystis carinii in renal insufficiency. Chest 74:91, 1978
Caterson RJ, Collett PV, Hood VL, Duggin GG, Horvath JS, Johnson JR, Sampson J, Tiller DJ: Trimethoprim/sulfamethoxazole and renal function in transplant patients. Clin Pharmacol Ther 23:553, 1978
Günther K, Traeger A, Stein G: Pharmakokinetik der Sulfonamid-Trimethoprim-Kombinationen Berlocombin und Sulprim bei Patienten mit verschiedenen Graden einer Nierenfunktionseinschränkung. Pharmazie 39:250, 1984
Halstenson CE, Blevins RB, Salem NG, Matzke GR: Trimethoprim-sulfamethoxazole pharmacokinetics during continuous ambulatory peritoneal dialysis. Clin Nephrol 22:239, 1984
Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:206, co-trimoxazole
Patel RB, Welling PG: Clinical pharmacokinetics of co-trimoxazole (trimethoprim-sulphamethoxazole). Clin Pharmacokinet 5:405, 1980
Richmond JM, Whitworth JA, Fairley KF, Kincaid-Smith P: Co-trimoxazole nephrotoxicity. Lancet 1:493, 1979
Rieder J, Schwartz DE, Fernex M, Bergan T, Brodwall EK, Blumberg A, Cottier P, Scheitlin W: Pharmacokinetics of the antibacterial combination sulfamethoxazole plus trimethoprim in patients with normal or impaired kidney function. Antibiot Chemother 18:148, 1974
Shouval D, Ligumsky M, Ben-Ishay D: Effect of co-trimoxazole on normal creatinine clearance. Lancet 1:224, 1978
Siber GR, Gorham CC, Ericson JF, Smith AL: Pharmacokinetics of intravenous trimethoprim-sulfamethoxazole in children and adults with normal and impaired renal function. Rev Infect Dis 4:566, 1982
Singlas E, Colin JN, Rottembourg J, Meessen JP, de Martin A, Legrain M, Simon P: Pharmacokinetics of sulfamethoxazole-trimethoprim combination during chronic peritoneal dialysis: Effect of peritonitis. Eur J Clin Pharmacol 21:409, 1982
Tasker PRW, MacGregor GA, de Wardener HE, Thomas RD, Jones NF: Use of co-trimoxazole in chronic renal failure. Lancet 1:1216, 1975
Watson ID, Stewart MJ, Wiles A, McIntosh SJ: Pharmacokinetics of two dosage levels of trimethoprim to ‘steady-state’ in normal volunteers. J Int Med Res 11:137, 1983
Main references
Bastow MD, Woods HF, Walls J: Persistent anemia associated with reduced serum vitamin B12 levels in patients undergoing regular hemodialysis therapy. Clin Nephrol 11:133, 1979
Chanarin I, Hutchinson M, McLean A, Moule M: Hepatic folate in man. Br Med J 1:396, 1966
Cooper BA: Megaloblastic anaemia and disorders affecting utilisation of vitamin B12 and folate in childhood. Clin Haematol 5:631, 1976
Hakami N, Neiman PE, Canellos GP, Lazerson J: Neonatal megaloblastic anemia due to inherited transcobalamin II deficiency in two siblings. N Engl J Med 285:1163, 1971
Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:1260, cyanocobalamin
Matthews DM, Beckett AG: Serum vitamin B12 in renal failure. J Clin Pathol 15:456, 1962
Reizenstein P, Ek G, Matthews CM: Vitamin B12 kinetics in man. Implications on total-body-B12 determinations, human requirements, and normal and pathological cellular B12 uptake. Phys Med Biol 11:295, 1966
Rosner F, Schreiber ZA: Serum vitamin B12 and vitamin B12 binding capacity in chronic myelogenous leukemia and other disorders. Am J Med Sci 263:473, 1972
Sevitt LH, Hoffbrand AV: Serum folate and vitamin B12 levels in acute and chronic renal disease. Effect of peritoneal dialysis. Br Med J 1969. 2:18
Stein G, Sperschneider H, Koppe S: Vitamin levels in chronic renal failure and need for supplementation. Blood Purif 3:52, 1985
Main reference
Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:1495, cyclandelate
Main reference
Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:450 cyclizine
Main references
Breimer DD, Winten MACM: Pharmacokinetics and relative bioavailability of cyclobarbital calcium in man after oral administration. Eur J Clin Pharmacol 9:443, 1976
Goldbaum LR, Smith PK: The binding of barbiturates by human and bovine serum albumin. Federation Proc 7:222, 1948
Kennedy AC, Lindsay EM, Briggs JD, Luke RG, Young N, Campbell D: Successful treatment of three cases of very severe barbiturate poisoning. Lancet 1:995, 1969
Main reference
Hucker HB, Stauffer SC, Albert KS, Lei BW: Plasma levels and bioavailability of cyclobenzaprine in human subjects. J Clin Pharmacol 17:719, 1977
Main reference
Mishima S: Clinical Pharmacokinetics of the eye. Proctor lecture. Invest Ophthal Vis Sci 21:504, 1981
Main references
Bagley CM, Bostick FW, DeVita VT: Clinical pharmacology of cyclophosphamide. Cancer Res 33:226, 1973
Bending MR, Finch RE: Hemodialysis during cyclophosphamide treatment. Br Med J 1:1145, 1978
Cheig JS, Reidenberg MM: Cyclophosphamide dose in renal failure. Am J Med 64:725, 1978
DeFronzo RA, Colvin OM, Braine H, Robertson GL, Davis PJ: Cyclophosphamide and the kidney. Cancer 33:483, 1974
D’Incalci M, Bolis G, Facchinetti T, Mangioni C, Morasca L, Morazzoni P, Salmona M: Decreased half-life of cyclophosphamide in patients under continual treatment. Eur J Cancer 15:7, 1979
DeVita VT, Adamson RH: Metabolism of 14C-cyclophosphamide. Prog Antimicrob Anticancer Chemother 2:218, 1970
Grochow LB, Colvin M: Clinical pharmacokinetics of cyclophosphamide. Clin Pharmacokinet 4:380, 1979
Humphrey RL, Kvols RK: The influence of renal insufficiency on cyclophosphamide induced hematopoietic depression and recovery. Proc Am Assoc Cancer Res 15:84, 1974
Juma FD, Rogers HJ, Trounce JR: Effect of renal insufficiency on the pharmacokinetics of cyclophosphamide and some of its metabolites. Eur J Clin Pharmacol 19:443, 1981
Kroener J, Green M: Cyclophosphamide dose in renal failure (Letter). Am J Med 64:725, 1978
Lopes VM: Cyclophosphamide nephrotoxicity in man. Lancet I:1060, 1967
Marbury TC, Wang LH, Lee CS, Majeske BL: Hemodialyzability of cyclophosphamide. Kidney Int 19:154, 1981
Milsted RAV, Jarman M: Haemodialysis during cyclophosphamide treatment. Br Med J 1:820, 1978
Mouridsen HT, Jacobsen E: Pharmacokinetics of cyclophosphamide in renal failure. Acta Pharmacol Toxicol (Copenh) 36:409, 1975
Wagner T, Heydrick D, Bartels H, Hohorst HJ: Einfluß von Leberparenchymschäden, Niereninsuffizienz und Hämodialyse auf die Pharmakokinetik von Cyclophosphamid und seinen aktiven Metaboliten. Arzneimittelforschung (Drug Res) 30:1588, 1980
Wang LH, Lee CS, Majeske BL, Marbury TC: Clearance and recovery calculations in hemodialysis: Application to plasma, red blood cell, and dialysat measurements for cyclophosphamide. Clin Pharmacol Ther 29:365, 1981
Main references
Goodman and Gilman’s The pharmacological basis of therapeutics. 7th ed. New York: Macmillan, 1985:1115, chapter 50, Antimicrobial agents by GL Mandell and MA Sande.
Kucers A, Mck.Bennett N (eds). The use of antibiotics, 3rd ed. London: Heinemann, 1979 p 457
Otten H, Plempel M, Siegenthaler W. (eds.) Antibiotika-Fibel: Sulfonamide. 4th ed. Stuttgart: Georg Thieme, 1975 p 583
Reed MD, Blumer JL: Clinical pharmacology of antitubercular drugs. Pediatr Clin North Am 30:177, 1983
Main references
Bozkurt E, Stierle H, Schollmeyer P, Keller E: Single-dose response kinetics of cyclosporine. Clin Nephrol 28:10, 1987
Fullath F, Wenk M, Vozeh S et al.: Intravenous cyclosporine kinetics in renal failure. Clin Pharmacol Ther 34:638, 1983
Impact of cyclosporine in medicine. Transplant Proc 20 (Suppl 2):3, 1988
Kahan BD: Cyclosporine nature of the agent and its immunologic actions. New York: Harcourt Brace Javanovich, 1988
Keller F, Walz G, Kunzendorf U, Haller H, Kramer W, Schwarz A, Offermann G: Initiale Pharmakokinetik und langfristiger Dosisbedarf von Cyclosporin. Nieren- und Hochdruckkrankh 16:294, 1987
Leithner C, Ulrich W, Schwarz M: Die Nephrotoxizität von Cyclosporin A. Nieren- und Hochdruckkrankh 15:529, 1986
Martindale The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:614, cyclosporin A
Myers BD, Ross J, Newton L, Luetscher J, Perlroth M: Cyclosporine-associated chronic nephropathy. N Engl J Med 311:699, 1984
Ptachcinski RJ, Venkataramanan R, Burckart GJ: Clinical pharmacokinetics of cyclosporin. Clin Pharmacokinet 11:107, 1986
Schindler R: Ciclosporin in Autoimmune Diseases. Berlin, Heidelberg, New York, Tokyo: Springer, 1985
Taube DH, Neild GH, Williams DG, Cameron JS, Hartley B, Ogg CS, Rudge CJ, Welsh KI: Differentiation between allograft rejection and cyclosporin nephrotoxicity in renal-transplant recipients. Lancet II:171, 1985
Thiel G (ed.): Experimental cyclosporine A nephrotoxicity; An International Workshop, Basle, 1985. Clin Nephrol 25 (Suppl 1):S2-S205, 1986
Venkataramanan R, Ptachcinski RJ, Burckart GJ, Yang SL, Starzl TE, Van Theil DH: The clearance of cyclosporin by hemodialysis. J Clin Pharmacol 24:528, 1984
Wonigeit K: Pharmakokinetik von Cyclosporin A und Bedeutung der Blutspiegelmessung für die Therapie. Internist 26:534, 1985
Yee GC, Lennon TP, Gmur DJ, Kennedy MS, Deeg HJ: Age-dependent cyclosporine: pharmacokinetics in marrow transplant recipients. Clin Pharmacol Ther 40:438, 1986
Main references
Hammerl H, Kindler K, Kränzl C, Nebosis G, Pichler O, Studlar M: Über den Einfluß von Cynarin auf Hyperlipidämien unter besonderer Berücksichtigung des Typs II (Hypercholesterinämie). Wien Med Wochenschr 123:601, 1973
Montini M, Levoni P, Ongaro A, Pagani G: Kontrollierte Anwendung von Cynarin in der Behandlung hyperlipämischer Syndrome. Beobachtungen von 60 Fällen. Arzneimittelforsch (Drug Res) 25:1311, 1975
Main references
Berger M, White J, Travis LB, Brouhard BH, Cunningham, III RJ, Patnode R, Petrusick T: Toxic psychosis due to cyproheptadine in a child on hemodialysis: A case report. Clin Nephrol 7:43, 1977
Fischer LJ, Thies RL, Charkowski D, Donham KJ: Formation and urinary excretion of cyproheptadine glucuronide in monkeys, chimpanzees, and humans. Drug Metab Dispos 8:422, 1980
Hintze KL, Wold JS, Fischer LJ: Disposition of cyproheptadine in rats, mice, and humans and identification of a stabile epoxide metabolite. Drug Metab Dispos 3:1, 1975
Hucker HB, Balletto AJ, Stauffer SC, Zacchei AG, Arison BH: Physiological disposition and urinary metabolites of cyproheptadine in the dog, rat and cat. Drug Metab Dispos 2:406, 1974
Kennedy KA, Halmi KA, Fischer LJ: Urinary excretion of a quaternary ammonium glucuronide metabolite of cyproheptadine in humans undergoing chronic drug therapy. Life Sci 21:1813, 1977
Porter CC, Arison BH, Gruber VF, Titus DC, Vandenheuvel WJA: Human metabolism of cyproheptadine. Drug Metab Dispos 3:189, 1975
Williams M, Martin GE: Selectivity of cyproheptadine as assessed by radioligand binding. J Pharm Pharmacol 34:58, 1982
Main reference
Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:1395, cyproterone acetate
Main references
Chabner B (ed.): Pharmacologic principles of chemotherapy, Philadelphia: WB Saunders, 1982 p 387
Donehower RC, Karp JE, Burke PJ: Pharmacology and toxicity of high-dose Cytarabine by 72-hour continuous infusion. Cancer Treat Rep 70:1059, 1986
Pallavivini MG: Cytosine arabinoside: Molecular, pharmacokinetic and cytokinetic considerations. Pharmacol Ther 25:207, 1984
Slevin ML, Piall EM, Aherne GW, Johnston A, Lister TA: The pharmacokinetics of cytosine arabinoside (ara-C) in the plasma and cerebrospinal fluid (CSF) during conventional and high-dose therapy. Med Pediatr Oncol 10 (Suppl 1): 157, 1982
Slevin ML, Johnston A, Woollard RC, Piall EM, Lister TA, Turner P: Relationship between protein binding and extravascular drug concentrations of a water-soluble drug, cytosine arabinoside. J R Soc Med 76:365, 1983
van Prooijen HC, Vierwinden G, Wessels J, Haanen C: Cytosine arabinoside binding to human plasma proteins. Arch Int Pharmacodyn Ther 229:199, 1977
Wan SH, Huffman DH, Azarnoff DL, Hoogstraten B, Larsen WE: Pharmacokinetics of 1-ß-d-arabinofuranosylcytosine in humans. Cancer Res 34:392, 1974
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 1991 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Seyffart, G. (1991). C. In: Drug Dosage in Renal Insufficiency. Springer, Dordrecht. https://doi.org/10.1007/978-94-011-3804-8_3
Download citation
DOI: https://doi.org/10.1007/978-94-011-3804-8_3
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-010-5692-2
Online ISBN: 978-94-011-3804-8
eBook Packages: Springer Book Archive